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1 Introduction 
Researchers involved in clinical trials for the evaluation of new treatment modalities for 
human African trypanosomiasis (HAT), also known as ‘sleeping sickness’, face a number 
of challenges that are rarely, if ever, encountered in this combination in other diseases. A 
large number of these challenges are related to the fact that both the disease and the 
populations it affects are ‘neglected’, and there is thus no background of generally 
accepted—and ubiquitously feasible—diagnostic and treatment standards that usually 
form the basis for the planning and conduct of clinical evaluation of new treatment 
modalities for a disease. 
Over the past years, interest in the evaluation and development of new treatment 
modalities has increased and it is thus timely to try to establish a common approach that 
will facilitate collaboration in the evaluation of new treatment modalities and/or facilitate 
comparison of data obtained by different groups. 
This Informal Consultation on Issues for Clinical Product Development for Human 
African Trypanosomiasis was convened: 
• To review and discuss the available data (which had been assembled and distributed in 
a briefing document, presented in the Appendix of the present report) with the very 
different organizations interested in the development of new treatment and diagnostic 
modalities for HAT; and  
• To develop a consensus framework to guide the planning, conduct and analysis of 
clinical trials in the future in a way that would promote the acquisition of data that can 
be readily compared and used in meta-analysis. 
The recommendations of the Informal Consultation were driven by the need for 
evaluation of the efficacy of new treatment regimens, but are in some cases directly 
applicable, in other cases easily adaptable, to the evaluation of new diagnostics. 
The recommendations focus on the acquisition of data from clinical trials, since data 
acquired according to common criteria are the prerequisite for any meaningful 
comparison between the outcomes of different clinical trials. 
With the objective of direct comparability of published data on drug efficacy in mind, 
recommendations for analysis and reporting of the efficacy of the treatment regimens 
under evaluation were also agreed upon. 
The Informal Consultation did not discuss approaches to harmonization of the evaluation 
of the safety of new treatment regimens for HAT. 
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2 Identification of patients for clinical trials 
2.1 Diagnosis 
Only patients who are trypanosome-positive should be included in clinical trials. 
• For evaluation of a patient’s eligibility for inclusion in a clinical trial, trypanosomes 
should be searched for in blood and lymph-node aspirate (when punctionable lymph 
nodes are present) and cerebrospinal fluid (CSF). 
• The most sensitive parasitological tests possible should be used as soon as possible 
after sample collection to retain maximum sensitivity. Repeated examinations (if 
possible, over several days) increase the probability of detecting trypanosomes. 
2.2 Staging 
To reduce the likelihood that the interpretation of the results of the clinical trial is 
confounded by factors other than those under investigation, the Informal Consultation 
recommended the use of the following criteria for staging and inclusion in clinical trials: 
• Staging should be based on parasitological criteria and on the white blood cell (WBC) 
count in the CSF. The amount of protein in the CSF should not be taken into account 
for disease staging as this parameter is not specific for HAT and normal values vary 
with age. 
• Patients eligible for enrolment in trials evaluating the treatment of first-stage (early or 
haemolymphatic) disease should have: 
 No trypanosomes in the CSF and a WBC count of ≤ 5 cells/µl CSF. 
• Patients eligible for enrolment in trials evaluating treatment of second-stage (late or 
meningoencephalitic) disease should have: 
 WBC count > 20 cells/µl CSF (with or without trypanosomes in the CSF). 
• Patients with the following characteristics should not be included in clinical trials 
aiming to recruit patients in the first or second stage of disease: 
 Patients with ≤ 5 WBC/µl CSF and trypanosomes in the CSF; 
 Patients with 6–20 WBC/µl CSF with or without CSF trypanosomes. 
Some of these patients can be cured with first-stage drugs, while others need treatment 
with second-stage drugs. Patients with these characteristics thus have a response to a 
specific drug under evaluation that does not allow conclusions to be reached as to the 
efficacy of the drug against first-stage or second-stage HAT. Consequently, the inclusion 
of such patients in a clinical trial of drugs to treat either first- or second-stage HAT would 
compromise the assessment of the efficacy of the drug in its intended patient population. 
Table 1 summarizes the consensus reached by the Informal Consultation regarding the 
inclusion of patients in clinical trials: 
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Table 1  
Diagnosis and staging-based criteria for inclusion of patients with HAT in clinical 
trials 
 
Targeted patient population Criteria 
First stage Trypanosome-positive blood and/or lymph 
Trypanosome-negative CSF 
≤ 5 WBC/µl CSF
a
 
 
Second stage Trypanosome-positive blood and/or lymph 
Trypanosome negative or positive CSF 
> 20 WBC/µl CSF
a
  
CSF: cerebrospinal fluid; HAT: human African trypanosomiasis; WBC: white blood cells 
a
 When the CSF contains > 20 red blood cells/µl, the patient should be excluded from the trial 
unless a non-haemorrhagic CSF sample is obtained later. 
 
2.3 Methodological considerations 
2.3.1 Diagnosis of patients to be included in clinical trials 
• In order to provide complete parasitological baseline characteristics for the patients 
enrolled in a clinical trial, blood and lymph (when punctionable lymph nodes are 
present) and CSF should be examined for parasites at least once, even if the presence 
of trypanosomes has already been demonstrated in another body fluid. 
• The most sensitive parasitological test possible should be used, i.e. mini-anion 
exchange centrifugation technique (mAECT) and/or capillary tube centrifugation 
(CTC) technique for blood examination, and modified single centrifugation or double 
centrifugation for CSF. Enlarged lymph nodes should be punctured for direct 
examination of lymph-node aspirate. 
• Experience in the field has shown that individuals may be incorrectly categorized as 
parasitological positives. Confirmation of the presence of trypanosomes in each body 
fluid by a second staff member is recommended as mandatory for clinical trials to 
reduce the risk of including false parasitological positives in the trial and to obtain 
accurate data on baseline characteristics. Appropriate training of all personnel 
involved in a trial is essential. 
2.3.2 Examination of CSF for staging 
• Lumbar puncture should be performed using sharp disposable needles. 
• A volume of 5 ml of CSF should be collected. It is important that the first drops be 
discarded to avoid contamination of the CSF with red blood cells. 
• Examination of the CSF for both trypanosomes and WBCs should be initiated not less 
than 5 minutes after collection and be completed within 30 minutes of CSF sampling, 
as CSF trypanosomes may die (and can thus no longer be detected) and CSF WBCs 
become deformed or disappear quite rapidly after collection of CSF. 
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• WBC counts: 
 Before the WBC count, the CSF should be gently mixed to obtain a 
homogeneous suspension of cells. Türck solution should not be used for 
three reasons: (1) as Türck solution lyses red blood cells, it is difficult to 
assess whether a sample is haemorrhagic; (2) Türck solution may lyse 
trypanosomes that were present in the CSF; (3) normal CSF cell counts are 
already close to the detection limit for counting chambers and adding Türck 
solution increases the volume/dilutes the sample and lowers the accuracy of 
the cell count. 
 When the CSF contains > 20 red blood cells/µl, the patient should be 
excluded from the trial unless a non-haemorrhagic CSF sample is obtained 
later. 
 All types of WBCs should be included in the WBC count, not only 
lymphocytes. Use of standardized, single-use counting chambers is advised 
in order to avoid variations in the volume of CSF, which can occur with 
incorrectly mounted classical counting chambers. The counting chamber 
should never be filled straight from the lumbar puncture needle while the 
CSF is being collected, to avoid incorrect filling of the chamber. 
 When the number of WBCs in a single CSF aliquot is < 30 per µl, the cell 
count should be performed on a second aliquot and the average of the two 
cell counts should be used for staging. 
• The modified single centrifugation or the double centrifugation technique should be 
used to detect trypanosomes in the CSF. The former technique is preferable because of 
its rapidity, simplicity and lower workload. It has been reported that no difference in 
sensitivity has yet been demonstrated between the two methods (Miézan et al., 1994a; 
Miézan et al., 2000). 
2.3.3 Evaluation of patients at end-of-treatment and at post-treatment follow-up 
• Within 1–2 days of the end of treatment (at the latest within 14 days of the end of 
treatment), an ‘end-of-treatment (EoT)
1
 evaluation’parasitological examinations on 
blood and lymph (when punctionable lymph nodes are present)should be 
performed. CSF examination at that time is indicated only for trials in which second-
stage patients are enrolled and to determine the appropriate rescue treatment for first-
stage patients with parasites in the blood and/or lymph. 
• In trials in which first-stage patients are enrolled as well as in trials enrolling second-
stage patients, parasitological examinations on blood and lymph (when punctionable 
lymph nodes are present) and CSF examination should be performed at each follow-
up after the EoT evaluation. 
                                                 
1
 EoT evaluation, protocol-planned timing within 1–2 days, and at the latest within 14 days after the end of 
treatment. 
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• The full spectrum of parasitological tests, including the most sensitive tests available 
(CTC and/or mAECT) for blood, double or improved single centrifugation for CSF, 
should be used to increase the sensitivity of detection of non-responders and relapsing 
patients (Miézan et al., 1994a).Provisions for confirmation of trypanosome presence 
by a second staff member should be included in the protocol to reduce the risk of false 
positives. 
• Given the relatively low prevalence of infection in most areas in which the disease is 
endemic, the probability that patients diagnosed as relapses are actually re-infections 
is likely to be small. Until validated field-usable methods allow an unambiguous 
distinction to be made between re-infection and relapse, no distinction will be made 
and all patients that are trypanosome-positive during post-treatment follow-up will be 
classified as relapses. 
2.4 Collaboration between clinical trial teams and national control 
programmes for identification of patients for clinical trials 
Because of the relatively low prevalence of HAT in most areas in which it is endemic, 
large numbers of people need to be screened (see Appendix, briefing document, 
section 3.2) to enrol the required number of patients. 
Effective detection of patients for clinical trials is thus best carried out via close 
collaboration between the clinical-trial team and the national control programme and/or 
the nongovernmental organization conducting HAT control in the area where the trial is 
taking place. Such collaboration requires considerable flexibility from the collaborating 
groups, e.g. mobile screening teams may need to change their originally scheduled 
screening tours and target villages as close as possible to the clinical study centre to 
facilitate follow-up after treatment. On the other hand, the clinical trial team needs to be 
sensitive to the mobile team’s capacity and experience. 
During discussions by the clinical-trial team and the mobile-screening team regarding the 
criteria for referral or transport of patients to the clinical trial centre for further evaluation, 
factors such as the local prevalence of disease need to be taken into account. To what 
extent patients screened by the local mobile team are further evaluated by that team or in 
the clinical trial centre will depend on the capacity of the mobile team as well as on the 
capacity of the clinical trial centre. The clinical trial should not have a negative impact on 
the normal functioning of the centre and care for other patients. Whenever possible, a 
special clinical-trial team should assist the local mobile team. 
The card agglutination test for trypanosomiasis (CATT) on whole blood is nowadays 
applied by all control programmes for screening of the population in areas in which 
Trypanosoma brucei gambiense is endemic. In order not to overburden the screening 
teams, only those individuals who have a positive CATT result at a serum dilution of 1:4 
or higher should undergo parasitological examinations. The CATT is not currently used 
for screening in areas in which T. b. rhodesiense is endemic. 
These requirements need to be taken into account during preparation and budgeting of the 
clinical trial. 
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3 Evaluation of new surrogate markers 
There is an urgent need for further validation of existing surrogate markers and for the 
identification of new markers that could allow the sensitivity of diagnosis to be increased, 
the evaluation of the treatment response to be improved and/or the post-treatment follow-
up period to be reduced. 
Consequently, surrogate markers (e.g. IgM titres, HAT-specific antibody titres) should be 
evaluated whenever possible in the context of clinical studies designed for other purposes, 
e.g. clinical trials of new treatment modalities. 
The timing of the test-of-cure visit (ToC)
2
 and the definitions of categories for disease 
stage and response, as proposed in the present document (see sections 4 and 5), should be 
reviewed and refined when appropriate, as validated surrogate markers become available. 
The requirement for lumbar puncture for the reliable diagnosis of second-stage disease 
and, in particular, the requirement for repeated lumbar punctures for the timely diagnosis 
of relapse, is a major problem for patient care, disease control and clinical trials. 
Surrogate markers that have the potential to allow staging and detection of relapse without 
lumbar puncture, whether for use in disease control or ‘only’ for clinical trial use, should 
be given priority for evaluation and validation. 
4 Time-point for final assessment of efficacy (ToC visit) 
In HAT control programmes, the final assessment of the efficacy of treatment for HAT is 
currently scheduled at 24 months after treatment; this is based on the recommendations of 
the 1986 meeting of the WHO Expert Committee on Epidemiology and Control of 
African Trypanosomiasis regarding the minimum follow-up period required before 
treatment can be considered successful. The data on which this recommendation was 
based are not provided in the WHO Expert Committee report (WHO Expert Committee 
on Epidemiology and Control of African Trypanosomiasis, 1986). 
Requirements for the assessment of efficacy in clinical trials are different from those for 
efficacy assessment in HAT control programmes. Prior experience has shown that 
quantification of the efficacy of a treatment modality 24 months after treatment is not as 
robust as would be desirable, since at that time data on patients’ status are missing for 
between 20% and 80% of treated patients. Therefore, the Informal Consultation discussed 
whether another time-point after treatment would provide a more reliable assessment of 
efficacy. Data relevant for this discussion were assembled by the preparatory committee 
who prepared the briefing document: 
• Data on time of relapse after treatment (see Table A1.13); 
• Data on patient follow-up rates at different times after treatment (see Table A1.14). 
                                                 
2
 Test-of-cure evaluation (final efficacy assessment), protocol-planned timing 18 months after treatment 
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On the basis of a discussion of the proportion of treated patients diagnosed as relapsed at 
different time-points after treatment, the associated follow-up rates and the reliability of 
the data, the following conclusions were reached: 
• The categorized data assembled in the briefing document suggest that at least 70% of 
relapses known to take place between 24 and 36 months after treatment have already 
occurred within 18 months after treatment, and that between at least 40% and 100% of 
relapses have already occurred within 12 months after treatment. 
• The variability in the percentage of patients diagnosed as relapsed at certain time-
points after treatment is likely to be related to a number of factors including, but not 
limited to: 
 The number of follow-up investigations per patient and the percentage of 
patients who have follow-up examinations at different time-points after 
treatment; 
 The times after treatment at which the follow-up examinations took place, 
i.e. post-treatment examinations at a sufficient number of time-points after 
treatment to allow detection of relapse at a time close to when relapse first 
becomes detectable; 
 Biological factors (e.g. differences in inclusion criteria, disease status at 
baseline); 
 Technical aspects of follow-up (methods employed, experience of 
investigators and technicians); 
 The criteria for relapse used by different control programmes and in 
different studies; 
 Differences in drugs and drug regimens used. 
• To test this hypothesis and potentially arrive at a more accurate estimate of time of 
relapse after treatment, an analysis of the raw data from studies/treatment programmes 
with acceptable and comparable quality of patient follow-up and data collection needs 
to be conducted, with stratification for factors that may influence time of relapse and 
time at which relapse was diagnosed. Organizations that have recently performed 
clinical trials (e.g. Médecins Sans Frontières, Malteser and the Swiss Tropical Institute) 
will provide raw data to be analysed. An informal working group will be formed to 
further discuss requirements for the data analysis. 
• Post-treatment follow-up data are available for a much higher percentage of patients at 
18 months than at 24 months, even in studies with active follow-up (see Table A1.14). 
The vast majority of patients who relapse within 24 months of treatment have already 
relapsed within 18 months (see Table A1.13). Therefore, efficacy assessment based on 
18 months post-treatment follow-up data would provide a good estimate of the 
efficacy of the drug under investigation, in particular in comparative studies. 
Consequently, 18 months can at this stage be recommended as the time for the final 
efficacy assessment (test-of-cure visit) in clinical studies. 
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• The percentage of patients with follow-up data is substantially higher at 12 months 
after treatment than at 18 months after treatment (see Table A1.14). Furthermore, the 
available data suggest that, in most case series or trials, the majority of relapses 
occurred within 12 months after treatment (see Table A1.13). Consequently, for a 
final efficacy assessment, post-treatment data acquired at 12 months may provide an 
equally good estimate of the efficacy of the drug under investigation as the data 
acquired at 18 months. The data in the Appendix, Tables A1.13 and A1.14 were 
obtained by different organizations using different protocols for data acquisition and 
analysis. The participants in the Informal Consultation felt that this limited the 
conclusions that could be drawn from these data. It was recommended that the raw 
data available from the different organizations be analysed and subsequently reviewed 
to determine whether they supported a recommendation for a final efficacy assessment 
based on follow-up data acquired at 12 months. 
• To ensure the timely diagnosis of relapse, patients should have follow-up evaluations 
at least at the end of treatment (including CSF examination for second-stage patients), 
and 3 or 6, 12 and 18 months after treatment. The choice of 3 or 6 months follow-up 
will depend on prior knowledge concerning the efficacy of the drug or treatment 
regimen under evaluation. To ensure data comparability between trials, clinical studies 
requiring assessments at other time-points should add these time-points, rather than 
replace the recommended evaluations at 3 or 6, 12 and 18 months after treatment. 
• To increase the number of patients with follow-up data acquired 18 months after 
treatment, it is recommended that the study protocol contains plans to continue efforts 
for several months after the 18 months post-treatment follow-up time-point has passed, 
to localize and evaluate patients who did not present for the 18 months assessment and 
were not previously diagnosed as relapsed. 
5 Patient evaluation and criteria for assessment of efficacy 
The limitations of the current methods for diagnosis and staging of HAT, in particular the 
low sensitivity with which trypanosomes are detected in blood, lymph and CSF, 
significantly affect patient follow-up, the decision on when to initiate rescue treatment 
and thus the assessment of the efficacy of treatment modalities. The reluctance or refusal 
of patients to come back for follow-up visits and undergo repeated lumbar punctures 
further aggravates these difficulties, since no data at all or no CSF data (presence or 
absence of trypanosomes, WBC count, or other CSF surrogate markers) may be available 
for the assessment of the patients’ state of health. 
These factors have certainly contributed to the use of different criteria to determine 
relapse by different investigators (see Appendix, briefing document, section 2.2) and to 
the introduction of a category of ‘suspected relapse’ and a category of ‘patients requiring 
close follow-up’ in many trials for patients with clinical signs and/or CSF WBC counts 
suggesting a relapse but without parasitological confirmation. 
The Informal Consultation discussed experience in the field, including experience with 
the reluctance of patients to undergo repeated lumbar punctures, the requirement for 
criteria suitable to achieve the right balance between treatment for relapse of a deadly 
disease as soon as necessary and not exposing patients to toxic treatments unnecessarily, 
as well as the requirement for a scientifically sound assessment of the efficacy of a 
treatment modality, and came to the following conclusions: 
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1 For clinical trials, an elaborate classification system is required for patients during 
follow-up. 
2 There are few hard data that could serve as the basis for objective, data-based 
criteria for the determination of response status in the absence of parasitological 
evidence. In the absence of such data, a complete set of objective criteria that 
cover the whole range of patient characteristics cannot be provided. 
Consequently, the criteria in the following tables refer to the investigator’s 
judgement for any decisions for which objective criteria are not available.
3
 
3 The lack of data on which to base objective criteria for the categorization of 
response status is one example reflecting the need for all institutions conducting 
clinical trials or treatment programmes to assemble comprehensive databases on 
the clinical and laboratory characteristics of all patients at each follow-up. 
Eventually these can be pooled and analysed for data on which recommendations 
for objective criteria can be based. 
4 Data to date suggest that an increase in the CSF IgM titre precedes the increase in 
CSF WBC counts and occurs before trypanosomes can be detected in the CSF. 
Consequently, an increase in CSF IgM titre may have prognostic value for relapse 
(Lejon et al., 2002). Since CSF IgM titre has not yet been validated as a surrogate 
marker/predictor of relapse, it should not be used to make treatment decisions. 
However, the data available do support the use of changes in CSF IgM titre for the 
identification of patients who should be monitored closely by the standard 
methods for detection of relapse (see patients with ‘uncertain evolution’ of 
disease). 
Figure 1 provides an overview of the recommended classification of patients at different 
times after treatment: end of treatment (EoT), during interim treatment follow-up (interim 
follow-up) and at the test-of-cure (ToC) at the last follow-up visit. The criteria for each 
classification are provided in sections  5.1 and  5.2 for patients with first-stage and second-
stage HAT, respectively. 
                                                 
3
  The judgment of the investigator, the criterion recommended here, could be replaced in a specific 
protocol by criteria agreed upon between sponsor(s) and investigator(s). 
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Figure 1 
Terminology for assessment of the patient after treatment 
 
 
 
 
Bold type End-point reached before ToC visit 
DE  Disease evolution 
EoT   End-of-treatment evaluation within 1–2 days, latest 14 days, after the end of treatment 
FU  Follow-up 
Interim FU  Interim follow-up: at 3 or 6 (depending on prior knowledge about the efficacy of  
  the drug or treatment regimen under evaluation) and 12 months after treatment 
LP   Lumbar puncture 
LT FU  Lost to follow-up 
ToC   Test-of-cure evaluation (final efficacy assessment) 18 months after treatment 
 
 
5.1 Patients with first-stage HAT 
5.1.1 Evaluation of first-stage patients at the end of treatment 
Within 1–2 days and at the latest within 14 days after the end of treatment, the protocol 
should plan for patients to be assessed for the presence of trypanosomes in the blood and 
lymph, when lymph-node aspirate examination is feasible. CSF examination is not 
regarded as necessary, except for non-responders who need lumbar puncture to determine 
the stage of the disease and thus appropriate rescue treatment. 
Depending on survival of the patient during treatment and outcome of the EoT evaluation, 
as applicable, patients will be classified as summarized in Table 2. 
Treatment
Death Non-responders
Rescue treatment
Responders Unknown response
Probable relapse 
Rescue treatment
Death Relapse 
Rescue treatment
Uncertain DE,
Intense FU
Favorable DE,
normal FU
No
FU
E
O
T
In
te
rim
 F
U
T
O
C
No
FU
LT
FU
Probable relapse 
Rescue treatment
Probable relapse 
Rescue treatment
Death
Death
Relapse 
Rescue treatment
Relapse 
Rescue treatment
Uncertain DE,
Intense FU
Probable cure
Further FU?
Favorable DE,
normal FU
Cure
E
O
T
In
te
rim
 F
U
T
O
C
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Table 2 
Criteria for classification of first-stage patients at the EoT evaluation 
 
Category Patient characteristics/Criteria  Action 
Death See section 5.1.4 for more details  
Non-responders  Patients with evidence of 
trypanosomes in blood and/or 
lymph 
They will receive rescue treatment as 
indicated by the stage of the disease 
determined at the EoT evaluation 
Responders  Patients with no evidence of 
trypanosomes in blood and/or 
lymph 
They will be scheduled for the next 
protocol planned follow-up visit 
Unknown 
response 
Patients for whom no EoT 
evaluation data are available 
All attempts should be made to 
evaluate these patients as soon as 
possible 
EoT: end-of-treatment 
 
5.1.2 Evaluation of first-stage patients during interim follow-up 
To ensure timely diagnosis of relapse, interim follow-up evaluations, including lumbar 
puncture, should be performed 3 or 6 months (depending on prior knowledge concerning 
the efficacy of the drug or treatment regimen under evaluation) and 12 months after 
treatment. Additional follow-up visits should be scheduled if indicated by the protocol or 
clinically (e.g. when the patient is classified as having ‘uncertain evolution’ of the 
disease). 
Depending on the survival of the patient during follow-up, availability of follow-up 
evaluation data and outcome of the evaluations, it is recommended that patients be 
classified as shown in Table 3. 
5.1.3 Test-of-cure evaluation for first-stage patients 
At the test-of-cure visit 18 months after treatment, parasitological examination of the 
blood and lymph (when feasible) and CSF examination should be performed and patients 
classified as shown in Table 4. 
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Table 3 
Criteria for classification of first-stage patients (with positive or unknown response at EoT evaluation) during interim follow-up visits  
 
Category Patient characteristics/Criteria Action 
Death See section 5.1.4 for more details  
Relapse Patients in whom trypanosomes have been detected in any body fluid  Rescue treatment as per study protocol 
Probable 
relapse 
Patients without parasitological evidence of relapse in any body fluid AND 
with > 20 WBC/µl CSF AND 
whose CSF is not haemorrhagic and WBC count is unlikely to be due to a disease other than HAT 
Patients without parasitological evidence of relapse in blood and lymph 
who refuse lumbar puncture OR whose CSF sample is haemorrhagic without trypanosomes AND 
who in the opinion of the investigator require immediate rescue treatment based on a marked 
deterioration of their clinical condition unlikely to be due to another disease than HAT 
Rescue treatment as per study protocol. 
Note: all possible efforts should be 
undertaken to convince a patient 
suspected of relapse to undergo lumbar 
puncture before classification as 'probable 
relapse' and thus the decision to 
administer rescue treatment 
Uncertain 
evolution 
Patients without parasitological evidence of relapse in any body fluid AND 
with 6–20 WBC/µl CSF in a non-haemorrhagic sample 
Patients without parasitological evidence of relapse in blood and lymph 
who refuse lumbar puncture OR whose CSF sample is haemorrhagic without trypanosomes AND 
who do not present with a marked clinical deterioration compared to the previous evaluation AND 
who in the opinion of the investigator should have an additional follow-up investigation in 1 or 3 
months 
In studies that determine the CSF IgM titer:  
Patients without parasitological evidence of relapse in blood and lymph AND 
with < 20 WBC/µl CSF AND 
with an at least fourfold increase in the LATEX/IgM CSF titer compared with the last evaluation (only 
valid for CSF that is not haemorrhagic) 
Additional follow-up after 1–3 months with 
clinical evaluation and evaluation of 
blood, lymph and CSF 
Favourable 
evolution 
Only patients who undergo lumbar puncture and whose CSF sample is not haemorrhagic can be 
classified as 'favourable evolution' if they are: 
Patients with ≤ 5 WBC/µl CSF and no parasitological evidence of relapse  
These patients will be scheduled for the 
next protocol planned follow-up visit  
CSF: cerebrospinal fluid; EoT: end-of-treatment; HAT: human African trypanosomiasis; Ig: immunoglobulin; WBC: white blood cell 
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Table 4 
Criteria for classification of first-stage patients (with positive or unknown response at EoT and not diagnosed as relapsed or 
probably relapsed at an interim follow-up
a
 assessment) at 18 months ToC visit 
 
Category Patient characteristics/Criteria Action 
Death See section 5.1.4 for more details  
Relapse Patients in whom trypanosomes have been detected in any body fluid. Rescue treatment as per study protocol. 
Probable relapse Patients without parasitological evidence of relapse AND 
with > 20 WBC/µl CSF AND 
whose CSF is not haemorrhagic and WBC count is unlikely to be due to a disease other 
than HAT. 
Patients without parasitological evidence of relapse in blood and lymph 
who refuse lumbar puncture OR whose CSF is haemorrhagic without trypanosomes AND 
who in the opinion of the investigator require rescue treatment, because they present a 
marked deterioration of their clinical condition that is unlikely to be due to another 
disease than HAT 
Rescue treatment as per study protocol 
Note: all possible efforts should be 
undertaken to convince a patient suspected 
of relapse to undergo lumbar puncture prior 
to classification as 'probable relapse' and 
thus the decision to administer rescue 
treatment 
Probable cure Patients without parasitological evidence of relapse AND 
with 6–20 WBC/µl CSF in a non-haemorrhagic sample 
Patients without parasitological evidence of relapse in blood and lymph AND 
who refuse lumbar puncture OR whose CSF is haemorrhagic AND 
who in the opinion of the investigator do not require rescue treatment because their 
clinical condition is satisfactory or their symptoms are attributed to a disease other than 
HAT 
Cure Only patients who undergo lumbar puncture and whose CSF sample is not haemorrhagic 
can be classified as cured if they are: 
Patients with ≤ 5 WBC/µl CSF and no parasitological evidence of relapse.  
 
 
Further follow-up at 24 months is not 
required for clinical trial data purposes 
Depending on the prior follow-up history of 
the patient, the investigator may decide to 
follow the patient further at the clinical trial 
centre or refer him to the nearest national 
control programme facility for routine follow-
up 24 months after treatment 
 
CSF: cerebrospinal fluid; EoT: end-of-treatment; HAT: human African trypanosomiasis; ToC: test-of-cure; WBC: white blood cell 
a
Interim follow-up examinations for efficacy and safety are conducted between the EoT evaluation and the ToC evaluation, protocol planned timing at 3 or 6 
(depending on prior knowledge about the efficacy of the drug) and at 12 months after treatment 
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5.1.4 Deaths 
Patients who died during treatment or during follow-up will be categorized based on the 
likely or definite cause of death: 
• Human African trypanosomiasis; 
• Adverse events regarded by the investigator as possibly, probably or definitely related 
to treatment for HAT; 
• Causes unrelated to HAT or treatment for HAT; 
• Unknown causes. 
Before classification of a patient as having died due to unknown causes, attempts should 
be made to determine the cause of death. In the case of death during follow-up, interviews 
of family members and neighbours or local health-care workers (sometimes referred to as 
‘oral autopsy’) may provide the likely cause of death. ‘Suggestive questioning’ should be 
avoided. Standardization of techniques for oral autopsy between clinical trials should be 
discussed. 
5.2 Patients with second-stage HAT 
5.2.1 Evaluation of second-stage patients at EoT 
Within 1–2 days and at the latest within 14 days after the EoT, the protocol should plan 
for the patients to be assessed for the presence of trypanosomes in the blood, lymph (when 
feasible) and CSF (EoT evaluation). Because CSF WBC counts may not have normalized 
at that time, they should not be taken into account for classification as responder or non-
responder (Dumas & Girard, 1978). Depending on survival of the patient during treatment 
and outcome of the EoT evaluation, as applicable, patients will be classified as shown in 
Table 5. 
 
Table 5 
Criteria for classification of second-stage patients at the EoT evaluation 
 
Category Patient characteristics/Criteria  Action 
Death See section 5.1.4 for more details  
Non-responders  Patients with evidence of trypanosomes  They will receive rescue treatment as per 
study protocol 
Responders  Patients with no evidence of 
trypanosomes 
They will be scheduled for the next follow-
up visit 
Unknown 
response  
Patients for whom no data on EoT 
evaluation are available 
All attempts should be made to evaluate 
these patients as soon as possible 
EoT: end-of-treatment 
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5.2.2 Evaluation of second-stage patients during interim follow-up 
To ensure timely diagnosis of relapse, interim follow-up evaluations, including lumbar 
puncture, should be performed at least 3 or 6 months (depending on prior knowledge 
concerning the efficacy of the drug or treatment regime under evaluation) and 12 months 
after treatment. Additional follow-up visits should be scheduled if indicated by the 
protocol or clinically (e.g. when the patient is classified as having ‘uncertain evolution’ of 
the disease). 
Depending on the survival of the patient during follow-up, availability of follow-up data 
and outcome of the evaluations, patients will be classified as shown in Table 6. 
These recommendations, even more than those for first-stage patients, leave the 
establishing of criteria for diagnosing patients with ‘probable relapse’ (resulting in rescue 
treatment) or ‘uncertain evolution’ of the disease (resulting in close follow-up) to those 
responsible for the study protocol, i.e. dependent on sponsor and investigator agreement 
(see section 5). 
The rationale for these recommendations is that there are currently not sufficient data on 
the relationship between WBC counts (or other surrogate markers of infection) and 
parasitological and clinical evidence of cure and relapse. Several studies have been 
recently completed or are about to be completed that have collected relevant data. Once 
an analysis of these data has been completed, the data and data analysis will be reviewed 
by experts to see whether they provide a sufficient basis for evidence-based criteria for 
patient classification during follow-up. 
5.2.3 ToC evaluation of second-stage patients 
At the ToC visit 18 months after treatment, parasitological examination of the blood, 
lymph (when feasible) and CSF should be performed and patients classified as shown in 
Table 7. 
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Table 6 
Criteria for classification of second-stage patients (with positive or unknown response to treatment at EoT) during interim follow-up
a
 
visits 
 
Category Patient characteristics/Criteria Action 
Death See section 5.1.4 for more details.  
Relapse Patients in whom trypanosomes have been detected in any body fluid at any follow-up visit. Rescue treatment as per study protocol 
Probable 
relapse 
Patients without parasitological evidence of relapse in any body fluid AND 
who, in the opinion of the investigator, require rescue treatment, because they present a marked 
deterioration of their clinical condition unlikely to be due to another disease than HAT and/or they 
have CSF WBC counts suggestive of relapse in the investigator's assessment and/or their CSF was 
haemorrhagic. 
Rescue treatment as per study protocol 
Note: all possible efforts should be 
undertaken to convince a patient suspected of 
relapse to undergo lumbar puncture prior to 
characterization as 'probably relapsed' and 
thus the decision to administer rescue 
treatment 
Uncertain 
evolution 
Patients without parasitological evidence of relapse in any body fluid AND 
who, in the opinion of the investigator, should have a follow-up investigation in 1–3 months because 
they present e.g.: 
with a deterioration of their clinical condition that might or might not be due to HAT AND/OR 
they have a rising CSF WBC count that might or might not be due to HAT, in the investigator's 
assessment 
Additional follow-up after 1–3 months with 
evaluation of blood, lymph and CSF 
 
Favourable 
evolution 
Only patients who undergo lumbar puncture and whose CSF is not haemorrhagic can be classified 
as 'favourable evolution' IF they are 
Patients without parasitological evidence of relapse AND 
≤ 20 WBC/µl CSF OR 
> 20 WBC/µl CSF AND decreased from previous values 
These patients will be scheduled for the next 
follow-up visit as applicable within the regular 
3 or 6, 12 and 18 months follow-up schedule 
in the protocol 
CSF: cerebrospinal fluid; EoT: end-of-treatment; HAT: human African trypanosomiasis; ToC: test-of-cure; WBC: white blood cell 
a 
Interim follow-up examinations for efficacy and safety are conducted between the EoT evaluation and the ToC evaluation, protocol planned timing at 3 or 6 
(depending on prior knowledge about the efficacy of the drug) and at 12 months after treatment
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5.2.4 Deaths 
Patients who died during treatment or during follow-up will be categorized on the basis of 
likely or definite cause of death, as described in section  5.1.4. 
6 Quantification of efficacy 
Ideally, all subjects within a clinical trial or treatment protocol/series should comply with 
all inclusion/exclusion criteria, be treated exactly as planned in the protocol and have a 
complete set of follow-up data. In practice, this is never the case, and thus the question 
arises as to which patients and which data to include in a particular analysis. To ensure an 
unbiased analysis of the data, the analyses to be conducted should be clearly specified 
before initiation of the study, i.e. in the study protocol. 
The major sources of potential bias discussed during the meeting of the Informal 
Consultation included criteria for: 
• Inclusion or exclusion of patients in particular analyses; 
• How to deal with missing follow-up or final efficacy evaluation data; 
• How to include those patients in the analysis of efficacy at a specific time-point during 
the study whose follow-up data had not been obtained within the time periods planned 
in the protocol. 
In addition, the Informal Consultation discussed the type of efficacy analyses to be 
conducted and the definition of a common nomenclature. 
Analyses and reporting of efficacy according to the nomenclature and criteria 
recommended below would facilitate the direct comparison of data reported for different 
clinical studies and treatment protocols/series. 
The discussions and the resulting definitions and recommendations for data analysis were 
based on the guidelines for statistical analysis 
(http://www.ich.org/LOB/media/MEDIA485.pdf) issued by the International Conference 
on Harmonization of Technical Requirements for Registration of Pharmaceuticals for 
Human Use (ICH, www.ich.org). 
6.1 Analysis populations 
Definition of criteria for the inclusion/exclusion of patients for specific analyses, i.e. 
definition of ‘analysis sets’ or ‘analysis populations’, should be included in the protocol. 
The nomenclature outlined in Table 8 is commonly used and was recommended by the 
Informal Consultation. 
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Table 7 
Criteria for classification of second-stage patients at the ToC visit at 18 months 
 
Category Patient characteristics/Criteria Action 
Death  See section 5.1.4 for more details  
Relapse Patients in whom trypanosomes have been detected in any body fluid Rescue treatment as per study 
protocol 
Probable 
relapse 
Patients without parasitological evidence of relapse in any body fluid AND 
with > 20 WBC/µl CSF AND whose WBC count cannot be explained by a disease other than HAT 
Patients without parasitological evidence of relapse in blood and lymph 
who refuse lumbar puncture OR whose CSF is haemorrhagic without trypanosomes AND who in the opinion 
of the investigator require rescue treatment because a marked deterioration of their clinical condition unlikely 
to be due to another disease than HAT 
Rescue treatment as per study 
protocol 
Note: all possible efforts should be 
undertaken to convince a patient 
suspected of relapse to undergo 
lumbar puncture prior to classification 
as 'probable relapse' and thus the 
decision to administer rescue 
treatment 
Probable cure Patients without parasitological evidence of relapse in blood and lymph AND 
who refuse lumbar puncture OR whose CSF sample is haemorrhagic without trypanosomes AND 
whose clinical condition is satisfactory OR 
whose clinical status is unlikely to be due to HAT 
 
Cure Only patients who undergo lumbar puncture and whose CSF is not haemorrhagic can be classified as cured if 
they are: 
Patients with ≤ 20 WBC/µl CSF and no parasitological evidence of relapse 
Further follow-up at 24 months is not 
required for clinical trial data purposes. 
Depending on the prior follow-up 
history of the patient, the investigator 
may decide to follow the patient further 
at the clinical trial centre or refer him to 
the nearest national control 
programme facility for routine follow-up 
24 months after treatment 
 
CSF: cerebrospinal fluid; HAT: human African trypanosomiasis; ToC: test-of-cure; WBC: white blood cell 
  
19 
Criteria for defining analysis sets for efficacy populations discussed and recommended 
are provided in Table 9. Considering that in the first clinical trial of a new drug or new 
drug combination, the percentage of subjects who were parasite-free at the EoT may be 
the primary efficacy variable, a ‘modified full analysis set’ has been defined. 
The efficacy parameters to be calculated for the analysis sets are described in Table 14. 
 
Table 8 
Nomenclature for analysis sets 
 
Analysis set  Comments 
Full analysis set, 
‘intention-to-
treat’ population 
The 'full analysis set' includes ideally all subjects randomized in a clinical trial 
(or treated within a treatment protocol/case series). 
Exclusion of randomized subjects is acceptable only under circumstances 
where there is no danger of biasing the analysis outcome through this 
exclusion (e.g. the patient did not receive a single dose of treatment, or there 
are no follow-up data available that would allow the effect of the drug in that 
patient to be assessed). 
The ‘intention-to-treat' analysis is regarded as the best way to assess the 
effect of a treatment policy, i.e. as an analysis that approximates the effect of 
treating according to a specific treatment policy in ' real life'. Consequently, 
for the 'full analysis set' or 'intent-to-treat' analysis, subjects are analysed as 
if they had received the treatment they were randomized to even if they 
received only a single dose of treatment, or actually received another 
treatment than the one to which they were randomized. 
Per-protocol set, 
‘per-protocol’ 
population 
The 'per-protocol set' ideally includes subjects who have been enrolled and 
treated as planned in the protocol and for whom final efficacy data are 
available (i.e. subjects who reached a protocol defined end-point (e.g. 
discontinuation of treatment owing to treatment-related adverse events, 
death, relapse) before the end of treatment or before the end of the protocol-
defined follow-up period (see boxes in bold type in Figure 1) and patients for 
whom efficacy data at the test-of-cure visit are available).  
In some cases a 'per-protocol set' may be defined up-front, that also includes 
patients who have received only a pre-specified minimum amount of 
treatment (expected to have the minimum level of efficacy that the drug 
should have to perform its planned role in patient management/disease 
control) but not the full planned treatment, and/or patients who did not 
comply with specific requirements in the protocol (e.g. certain 
inclusion/exclusion criteria, concomitant treatment, concomitant diseases).  
This analysis set can be referred to as the 'modified’ per-protocol set to 
distinguish it from the 'ideal' per-protocol set.  
The results of the 'per-protocol' analysis will allow conclusions as to the 
validity of the hypothesis underlying a clinical trial, i.e. that the drug under 
investigation, if administered as planned to a specific type of patient (defined 
via the inclusion and exclusion criteria in the protocol) will have a certain 
efficacy (with the level of efficacy expected (e.g. percentage of subjects 
cured, or superior to the comparator drug, or non-inferior to the comparator 
drug) specified in the protocol, usually in the sample size justification.  
Safety analysis 
set 
The 'safety analysis set' includes all subjects who received at least one dose 
of the drug. 
Including all subjects who received at least one dose of the study drug 
allows the safety profile of the drug to be fully characterized among the 
patients being treated, including adverse events which result in treatment 
discontinuation after only one or few doses (e.g. allergies, other symptoms of 
intolerance). 
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The defined minimum amount of treatment required for inclusion in the per-protocol and 
the modified-full-analysis population is drug-specific. For currently available drugs used 
as comparators, the minimum amount of treatment (to be specified in the protocol) is 
provided in Table 10. 
 
Table 9 
Analysis sets for efficacy analysis
a
 
 
Analysis set Patients included 
Full analysis set 
(intention-to-treat 
population)  
All patients enrolled in the study 
who received at least one dose of study medication 
AND 
who died during treatment or were non-responders OR for whom 
efficacy evaluation data at the test-of-cure visit or a protocol 
defined earlier time-point are available. 
Per-protocol set All patients enrolled in the study 
in compliance with the inclusion/exclusion criteria 
AND 
who received at least one dose of study medication AND died 
during treatment or were non-responders OR for whom treatment 
was discontinued because of treatment-related adverse events 
OR 
who received the protocol-defined treatment AND 
who reached one of the protocol-defined end-points (death, non-
responder, relapse, probable relapse) before the ToC
b
 or have a 
ToC visit assessment. 
Modified per-protocol set All patients enrolled in the study 
with parasitologically confirmed infection 
AND 
who received at least one dose of study medication AND died 
during treatment or were non-responders OR were discontinued 
from treatment for treatment-related adverse events 
OR 
who received a defined minimum amount of treatment AND who 
reached one of the protocol defined end-points (death, non-
responder, relapse, probable relapse) OR for whom efficacy 
evaluation data at the ToC visit or a protocol defined earlier time-
point are available 
Safety-analysis set All patients enrolled in the study who received at least one dose of 
study drug 
ToC: test-of-cure 
a 
For trials with other efficacy end-points (e.g. trials evaluating a new drug or new drug 
combination for the first time), these criteria need to be adapted accordingly. 
b
 ToC evaluation (final efficacy assessment), protocol-planned timing 18 months after treatment 
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Table 10 
Minimum amount of treatment required for inclusion in the per-protocol analysis 
population 
 
Drug Standard treatment 
regimen 
Minimum amount of treatment for per-protocol 
population 
Melarsoprol 
for T. b. 
gambiense 
2.2 mg/kg per day IV x 10 
days 
8 days of treatment without interruption or up to one 
treatment interruption for ≤ 2 days  
 
Melarsoprol 
for T. b. 
rhodesiense 
Different schedules Decided by individual investigators until further field 
experience is available for evaluation  
Eflornithine 400 mg/kg per day IV x 
14 days 
12 days of treatment without interruption or 
up to two treatment interruptions for up to two 
successive doses 
Pentamidine 4 mg/kg per day IM x 7 
days 
Up to one treatment interruption of ≤ 2 days 
 
Suramin Different schedules Decided by individual investigators until further field 
experience is available for evaluation 
IM, intramuscular; IV, intravenous 
 
6.2 Time windows for assigning patient follow-up data to times after 
treatment, for efficacy analysis 
A protocol will usually plan for a specific action/evaluation to take place within a defined 
window around the ‘ideal’ time after treatment (for example the 3-month follow-up 
evaluation should be conducted at 3 months ± 1 week) (see Table 11, columns 1 and 2). In 
general, the time window during which a specific action should take place (e.g. taking of a 
blood sample) is rather narrow early in the study and becomes wider later in the study, 
because the influence of time-since-treatment on the exact value of the variable to be 
obtained (e.g. haemoglobin concentration, drug concentration) is expected to be less later 
in the study than earlier (e.g. for a pharmacokinetic analysis, the time window during 
which blood samples are to be taken during the first hours after drug administration is 
measured in minutes, while that spanning, for example, days 1–7 after treatment is in 
hours). 
It is unlikely that all patients will undergo an evaluation within the protocol-defined time 
windows. This is in particular true for the follow-up visits during the outpatient phase of 
the trial.  
To ensure an unbiased data analysis, time windows need to be defined (prior to the data 
becoming available for analysis) that determine into which analysis the data from a 
specific patient who has a follow-up visit outside the protocol-scheduled time windows is 
to be slotted. These time windows need to cover the whole follow-up period in a 
contiguous way, such that the data from all subjects can be included in the analysis, no 
matter how different the actual visit date is from the specific protocol-scheduled visit date. 
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The Informal Consultation recommended the use of the time windows and slotting rules 
described in Table 11. 
 
Table 11 
Slotting of actual follow-up visit time-points for efficacy data analysis 
 
Protocol plan Study conduct Data analysis 
Follow-up visit 
(ideal follow-up 
time) 
Protocol-defined 
acceptable time window 
around the ideal follow-
up time
a
 
Actual time follow-
up data are 
obtained for 
subjects 
Efficacy analysis time-
point to which the data 
will be assigned 
End of treatment Within 2 days, latest 14 
days after treatment 
1–30 days after end 
of treatment
b
 
End of treatment  
3 months At 3 months ± 1 week after 
end of treatment 
2–4 months after end 
of treatment 
3 months  
6 months At 6 months ± 2 weeks after 
end of treatment 
5–9 months after end 
of treatment 
6 months  
12 months At 12 months ± 4 weeks 
after end of treatment 
10–16 months after 
end of treatment 
12 months 
18 months At 18 months ± 4 weeks 
after end of treatment 
17–21 months after 
end of treatment 
18 months (test-of-cure 
visit) 
24 months At 24 months ± 4 weeks 
after end of treatment 
≥ 22 months after 
end of treatment 
Included in 18 months 
follow-up assessment 
(test-of-cure visit) for 
evaluation of efficacy of 
drugs 
Note: If the objective of 
the analysis is to 
determine the time of 
relapse after treatment 
and the follow-up data 
available support this, 
these data may be 
analysed separately 
a 
These time windows are provided for illustration only, and are not specifically recommended by 
the Informal Consultation. 
b
 In all cases, the time period begins on the first day of the first month and lasts until the last day 
of the last month. 
 
Given the considerations described in section 4 in particular, the fact that the participants 
in the Informal Consultation deemed that a follow-up time-point of 12 months could not 
be recommended at the present time, the window for the 18-months ToC visit was chosen 
to be asymmetrical (i.e. 17–21 months) to avoid the recommendation for an 18 months 
follow-up time-point becoming in reality a 17- or 16- or 15-months efficacy time-point. 
As a consequence and/or to avoid slotting people with very disparate follow-up time-
points, the windows around the 6- and 12-months follow-up time-points have different 
widths on the two sides of the preferred time-point. 
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For a clinical trial evaluating the efficacy of a drug, which includes patients who were not 
diagnosed as relapsed before the 18-month visit and who were not evaluated for ToC until 
well after 18 months (up to the last time after treatment for which the protocol requires 
attempts to be made to localize the patients), a differentiation between patients having 
their ToC visit at 18 months or at 24 months after treatment is in general not necessary. 
For data analyses designed to determine the fraction of patients relapsing at 12 versus 18 
versus 24 months of treatment, patients having their ToC visit e.g. 17 months and 
23 months after treatment should be analysed separately, provided that the follow-up data 
available justify such an analysis. 
An additional analysis with different data slotting may be indicated, depending on the 
objectives of the analysis. 
6.3 Handling of missing efficacy data 
Prior experience (see Table A1.14) shows that the number of patients with missing 
follow-up data for at least one planned follow-up time-point, is large, even in trials with 
active follow-up, and that this number increases with time since treatment. 
To ensure comparability of data from trials conducted by different investigators/sponsors, 
the way in which patients for whom data concerning the ToC visit are missing are 
included in the efficacy analysis should be uniform. Table 12 summarizes the 
recommendations for categorizing for quantification of efficacy among patients without a 
ToC evaluation and who have not reached a protocol-defined end-point (e.g. death, 
probable relapse, relapse) before the ToC visit. 
 
Table 12 
Inclusion into the efficacy analysis of patients who have not reached a protocol-
defined end-point and for whom there are no data for the 18 months test-of-cure 
visit 
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Table 12 
 
Results of interim follow-up evaluation Test-of-cure 
visit 
Inclusion 
into efficacy 
analysis as 
3 or 6 
months 
follow-up  
(≤ 9 months 
after 
treatment) 
Additional 
follow-ups 
(≤ 9 months 
after treatment) 
12 months 
follow-up  
(10–16 months 
after 
treatment) 
Additional 
follow-ups 
(10–16 months 
after treatment) 
18 months  
(17–21 months 
after treatment 
or ≥ 17 
months)
a
 
 
Missing NA Missing NA Missing Not included 
 
Missing NA UE Missing Missing Unknown 
Missing NA UE UE Missing Unknown 
Missing NA UE FE Missing PC 
Missing NA FE NA Missing PC 
 
UE UE or Missing Missing NA Missing Unknown 
UE UE or Missing UE Missing Missing Unknown 
UE UE or Missing UE UE Missing Unknown 
UE UE or Missing UE FE Missing PC 
UE UE or Missing FE NA Missing PC 
 
UE UE Missing NA Missing Unknown 
UE UE UE Missing Missing Unknown 
UE UE UE UE Missing Unknown 
UE UE UE FE Missing PC 
UE UE FE NA Missing PC 
      
UE FE Missing NA Missing Unknown 
UE FE UE Missing Missing Unknown 
UE FE UE UE Missing Unknown 
UE FE UE FE Missing PC 
UE FE FE NA Missing PC 
 
FE NA Missing NA Missing Unknown 
FE NA UE Missing Missing Unknown 
FE NA UE UE Missing Unknown 
FE NA UE FE Missing PC 
FE NA FE NA Missing PC 
FE, Favourable evolution; NA, Not applicable; PC, Probable cure; UE, Uncertain evolution. 
a 
See last two paragraphs in Table 11. 
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6.4 Efficacy variables 
6.4.1 Nomenclature 
A uniform use of different terms to refer to measures of the efficacy of a drug (as 
proposed in Table 13) in combination with uniform calculation of efficacy measures (as 
proposed in Table 14) will facilitate comparison between data reported from different 
trials and treatment protocols.  
 
Table 13 
Nomenclature for different measures of drug efficacy 
 
Variable  Drug effect referred to 
Treatment fatality 
rate 
Quantifies the lack of efficacy of the drug in terms of deaths attributable 
either to lack of curative effect or to toxicity. Subjects who died from 
unknown causes are included based on the considerations underlying 
their inclusion in the treatment failure rate. 
Treatment failure rate Quantifies failure of the drug to result in cure of patient independent of 
whether this failure is attributable to lack of efficacy or to toxicity of the 
drug. Since, in particular for regulatory purposes, the efficacy reported 
should be overstated, treatment failure should also include those 
patients who died from unknown causes (and for whom it is thus not 
certain that they did not die because of lack of efficacy or toxicity of the 
drug under evaluation) and who discontinued owing to toxicity of the 
drug. 
Relapse rate Quantifies the lack of efficacy of the drug via the number of patients who 
did not have detectable levels of trypanosomes at the end of treatment, 
but were diagnosed as relapsed or probably relapsed. 
Depending on the objectives of the analysis, the calculation of the 
overall relapse rate (i.e. including 'relapse' and 'probable relapse') may 
be complemented by the calculation of 'parasitologically confirmed 
relapse rate' and 'probable relapse rate'. 
Cure rate Quantifies the efficacy of the drug via the number of patients who were 
classified as 'cure' or 'probable cure'. 
Depending on the objectives of the analysis, the calculation of the 
overall cure rate (i.e. including 'cure' and 'probable cure') may be 
complemented by the calculation of 'parasitologically confirmed cure 
rate' and 'probable cure rate'. 
Response rate Quantifies the efficacy of the drug via the number of patients who were 
found to be parasite-free at the end of treatment. This measure is of 
particular importance for the first studies of new treatment or new 
combinations of established treatments. 
Non-response rate Quantifies the lack of efficacy of the drug in terms of its ability to clear 
trypanosomes from body fluids by the end of treatment. 
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6.4.2 Calculation of efficacy 
A series of efficacy variables to be calculated was defined on the basis of requirements for 
regulatory submissions for new drugs and comparative interpretation of results of 
different studies. Which of the efficacy variables defined below should be chosen as the 
primary efficacy variable will differ between different studies, depending on the 
objectives of the study (e.g. pivotal versus dose-finding study). 
The patients to be included in the nominator and denominator for the different measures 
of efficacy are provided in Table 14. Definition and criteria for the different response 
categories in the nominator are those provided in section 5 and Figure 1. 
Each of these variables can be calculated using different denominators, i.e. for different 
analysis populations as well as for different time-points after treatment (e.g. treatment 
failure rate at EoT or at a specified time-point during interim follow-up), depending on 
the objectives of the analysis. 
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Table 14 
Description of efficacy variables 
 
Variable Nominator Denominator 
Treatment 
fatality rate 
Sum of patients who: 
 died during treatment (likely) due to HAT 
 died during treatment (likely) due to treatment 
related adverse events 
 died during follow-up (likely) due to HAT 
 died during follow-up (likely) due to treatment 
related adverse events 
 died from unknown causes 
Safety analysis set 
Treatment failure 
rate 
Sum of patients who: 
 died during treatment due to HAT 
 died during treatment due to treatment-related 
adverse events  
 died during follow-up (likely) due to HAT 
 died during follow-up (likely) due to treatment-
related adverse events 
 died during treatment or follow-up due to unknown 
causes 
 were non-responders at EoT visit 
 relapsed  
 probably relapsed 
 were discontinued from study treatment due to 
treatment-related adverse events (and not cured) 
Full analysis set 
Relapse rate 
Overall relapse 
rate 
Sum of patients who: 
 relapsed  
 probably relapsed 
Full analysis set 
Per-protocol set 
Modified per-protocol set 
Parasitologically 
confirmed 
relapse rate 
Patients who: 
relapsed  
 
Full analysis set 
Per-protocol set 
Modified per-protocol set 
Probable 
relapse rate 
Patients who: 
 probably relapsed  
Full analysis set 
Per-protocol set 
Modified per-protocol set 
Cure rate 
Parasitologically 
confirmed cure 
rate 
Sum of patients who: 
 were cured 
 
Full analysis set 
Per-protocol set 
Modified per-protocol set 
Probable cure 
rate 
Sum of patients who: 
 were probably cured 
Full analysis set 
Per-protocol set 
Modified per-protocol set 
Response rate Patients: 
 who were responders at EoT visit 
Safety analysis set 
Full analysis set 
Non-response 
rate 
Patients: 
 who were non-responders at EoT visit 
Safety analysis set 
Full analysis set 
EoT: end-of-treatment; HAT: human African trypanosomiasis 
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1. Introduction 
The conduct of clinical trials for the evaluation of new treatment modalities for human 
African trypanosomiasis (HAT) faces a number of challenges that are rarely, if ever, 
encountered in this combination in other diseases. A large number of these challenges are 
related to the fact that both the disease and the populations it affects are neglected. Thus, 
there is no background of generally accepted—and ubiquitously feasible—diagnostic and 
treatment standards that usually form the basis for planning and conducting clinical 
evaluation of new treatment modalities for a disease. 
Over the past years, interest in evaluation and development of new treatment modalities 
has increased and it thus appears timely to try and establish a common approach that will 
facilitate collaboration in the evaluation of new treatment modalities and/or facilitate 
comparison of data obtained by different groups. 
This meeting has been convened for the very different organizations interested in the 
development of new treatment modalities for HAT to get together and discuss past 
experiences and current approaches to patient care and evaluation of new treatment 
modalities to see whether common approaches are desirable—and feasible.  
This document provides a short overview of major issues that the medical and scientific 
community face as a basis for the discussions during the meeting. While the data 
summarized deal with Trypanosoma brucei gambiense HAT, similar considerations apply 
to T. b. rhodesiense HAT. 
2. Diagnostic criteria 
2.1 Criteria for diagnosis of first- and second-stage African trypanosomiasis 
caused by T. b. gambiense 
2.1.1 Diagnosis 
The diagnosis of T. b. gambiense HAT follows a three-step pathway: screening, 
diagnostic confirmation and staging. For the purpose of screening of the population at risk 
for T. b. gambiense, detection of trypanosome-specific antibodies in blood by the card 
agglutination test for trypanosomiasis (CATT/T. b. gambiense), is currently used in most 
endemic areas. Diagnostic confirmation in CATT-positives or clinical suspects then relies 
on the finding of trypanosomes through microscopical examination of body fluids.  
Criteria for diagnostic confirmation of HAT are uniform when trypanosomes are detected 
in the blood, lymph nodes or CSF (parasitological confirmation). Because of the limited 
sensitivity of the parasitological techniques (see section 2.3.2) and the sometimes low 
parasitaemia, failure to demonstrate parasites does not necessarily exclude infection. 
Some control programmes/investigators/nongovernmental-organization treatment 
programmes, therefore, take into account additional criteria such as the end-dilution titre 
of CATT performed on serum dilutions and/or white blood cells (WBCs) in the CSF 
and/or clinical signs (examples in Table A1.1). 
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Table A1.1 
Control-programme case definition of HAT caused by T. b. gambiense, in 2001 
 
Country Case definition 
Benin, Cameroon, Guinea, 
Central African Republic, 
Chad, Togo 
Trypanosomes detected 
Democratic Republic of the 
Congo 
Trypanosomes detected OR 
No trypanosomes but clinical signs and > 5 WBC/µl CSF 
Gabon Trypanosomes detected OR 
No trypanosomes but CATT + ≥ 1/2  
Congo Trypanosomes detected OR 
No trypanosomes but CATT + ≥ 1/4  
Uganda Trypanosomes detected OR 
No trypanosomes but CATT + ≥ 1/4 and > 20 WBC/µl CSF 
Sudan
a
 Trypanosomes detected OR 
No trypanosomes but CATT + ≥ 1/4 and > 20 WBC/µl CSF OR 
No trypanosomes but CATT + ≥ 1/16 and prevalence of HAT 
among tested population > 2% 
Angola, Equatorial Guinea Trypanosomes detected OR 
No trypanosomes but CATT + ≥ 1/8 
CATT: card agglutination test for trypanosomiasis; CSF: cerebrospinal fluid; HAT: human African 
trypanosomiasis; WBC: white blood cells 
Source: Simarro et al. (2003). 
a 
Programme carried out by Médecins Sans Frontières, Switzerland, and reported in Chappuis et 
al. (2004). 
 
There is no universal algorithm for the diagnosis of HAT in cases that remain 
parasitologically unconfirmed. Criteria to define a CATT-positive case as a patient with 
HAT, to perform a lumbar puncture, and whether or not to follow up CATT-positives, 
differ substantially. These criteria are influenced by: 
• Different positive predictive values of CATT depending on HAT prevalence; 
• Workload; 
• Political situation, climate/season, transport and communication links, project 
means and resources. 
2.1.2 Staging 
Staging of the disease is a key step that allows classification of the patient into the first 
(haemolymphatic) stage or the second (meningoencephalitic) stage of the disease and is 
based on CSF examination. The WHO criteria (WHO, 1998) to diagnose second-stage 
infection in parasitologically confirmed cases are based on the presence in CSF of: 
• Trypanosomes; and/or 
• An elevated WBC count of > 5 WBC/µl; and/or 
• An elevated protein content (> 370 mg/l using the dye-binding assay). 
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It has been reported that protein determination from CSF has been abandoned almost 
completely due to the need for sophisticated material, instability of reagents, and limited 
additional information obtained from the analysis (Lejon et al., 2003). 
Although a cut-off of 5 cells/µl CSF is most widely applied, other cut-off criteria for the 
cell count are in use. Moreover, some organizations/countries apply different cut-offs for 
cell count in the CSF for parasitologically unconfirmed CATT-positives who are 
considered to be patients, than for individuals in whom infection was parasitologically 
confirmed in blood or lymph-node aspirate (Table A1.2). 
 
Table A1.2   
Criteria for second-stage HAT caused by T. b. gambiense  
 
Investigators Criteria Reference 
Clinical trials/Treatment programmes
 
MSF Sudan (2001 or 
later) 
Trypanosomes in CSF AND/OR 
> 5 WBC/µl CSF AND trypanosomes in blood 
or lymph OR 
≥ 20 WBC/µl CSF AND CATT titration ≥ 1/4 
AND absence of trypanosomes in blood or 
lymph 
Chappuis F, personal 
communication 
Malteser (June 2002 
or later) 
Burri et al. (2000) 
Milord et al. (1992) 
Trypanosomes in CSF AND/OR 
> 5 WBC/µl CSF 
Milord et al. (1992); 
Burri et al. (2000); 
Franco et al. (2004)  
WHO/TDR (2000) Trypanosomes in CSF AND/OR 
> 20 WBC/µl of CSF 
WHO 2000
 
Marion Merrel Dow, 
Eflornithine 
registration studies 
(1980s) 
Trypanosomes in the CSF, AND/OR 
elevated CSF WBC count, elevated CSF 
protein concentration, presence of detectable 
IgM end-dilution titers in CSF AND/OR 
characteristic signs and symptoms of CSF 
involvement 
WHO/TDR and Aventis 
(2003)
 
WHO/National control programmes
 
WHO Expert 
Committee  
Trypanosomes in CSF AND/OR 
> 5 WBC/µl CSF OR > 37 mg of protein/100 
ml (dye-binding protein assay) 
WHO (1998)
 
Democratic Republic 
of the Congo, Congo, 
Sudan 
Trypanosomes in the CSF AND/OR 
> 5 WBC/µl CSF 
Schmid et al. (2005)
 
Equatorial Guinea  Trypanosomes in the CSF AND/OR 
≥ 10 WBC/µl CSF 
Schmid et al. (2005)
 
Angola, Côte d'Ivoire Trypanosomes in the CSF AND/OR 
≥ 20 WBC/µl CSF 
Josenando (1994); 
Doua et al. (1996); 
Schmid et al. (2005)
 
CATT: card agglutination test for trypanosomiasis; CSF: cerebrospinal fluid; HAT: human African 
trypanosomiasis; TDR: UNDP/World Bank/WHO Special Programme for Research and Training in 
Tropical Diseases; WBC: white blood cells 
  38 
Some data on the percentage of second-stage patients who are categorized as such without 
detection of parasites are summarized in Table A1.3. 
 
Table A1.3   
Patients with HAT categorized as second-stage in the absence of parasites 
 
Trypanosome-
negative in all tests 
(staging based on 
CATT and WBC) 
Trypanosome-
negative CSF 
(staging based 
on WBC and 
signs and 
symptoms) 
References Site/study No. of 
second-
stage 
patients 
N  (%) N %  
MSF, Omugo, 
Uganda 
1785 112  (6.3) Data not 
available 
Priotto G, personal 
communication 
MSF, Ibba, 
Sudan 
3135 118 (3.6) Data not 
available 
Priotto G, personal 
communication 
MSF, Kiri, South 
Sudan 
1376 104 (7.6%) Data not 
available 
Chappuis F, personal 
communication 
Impamel I 500 103 (20.6%) 451 (90.7%) Burri C, personal 
communication 
Impamel II 2571 406 (15.8%) 1006 (39.1%) Schmid C, personal 
communication 
CATT: card agglutination test for trypanosomiasis; HAT: human African trypanosomiasis; MSF: 
Médecins Sans Frontières; WBC: white blood cells 
 
Questions for discussion 
1 Why are different criteria used for staging of T. b. gambiense HAT in the absence 
of trypanosomes in the CSF? 
2 What is the impact of different criteria for staging in the absence of trypanosomes 
in the CSF in terms of comparability of the results of different clinical studies? 
3 Can one/should one agree on common criteria for staging for clinical trial 
inclusion criteria? 
2.2 Criteria for diagnosing relapse 
2.2.1 Diagnosis of relapse in first-stage HAT 
The criteria for relapse after treatment for first-stage HAT and assessment of whether a 
relapsed patient is first-stage or second-stage are identical or similar to those for the 
diagnosis of the disease, depending on the criteria for initial diagnosis and staging used.  
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2.2.2 Diagnosis of relapse (or re-infection) in second-stage HAT 
Relapse is uniformly and unambiguously diagnosed by the presence of trypanosomes in 
blood, lymph, and/or CSF in patients in whom no trypanosomes were detectable 
immediately after the EoT. The data to distinguish between relapse and re-infection are 
usually not available and thus the number of patients diagnosed as relapsed possibly 
includes patients who have been re-infected. The probability of patients diagnosed as 
relapsed being re-infections will depend on the time after treatment and the infection rates 
in the areas where they live and is likely relatively small. 
If trypanosomes are not detected, diagnosis of relapse is based on the absolute number of 
WBCs and/or an increase in WBCs in the CSF with or without neurological symptoms of 
the disease. Criteria differ somewhat between different investigators/organizations 
conducting disease control or clinical studies. Table A1.4 provides an overview of criteria 
used. 
 
Table A1.4   
Criteria for diagnosing relapse of patients with second-stage HAT 
 
Investigator Criteria References
 
Malteser (2002) Trypanosomes in CSF, lymph node or blood 
AND/OR 
WBC/µl CSF clearly higher than at previous 
examination 
Franco et al. (2004) 
MSF (Uganda, Sudan) Trypanosomes in blood, lymph or CSF 
AND/OR 
> 20 WBC/µl of CSF at 24 months AND/OR 
> 20 WBC/µl of CSF at < 24 months and 
higher than the previous two counts AND/OR 
> 20 WBC/µl of CSF at < 24 months and 
neurological signs 
Priotto (2004); 
Chappuis (2004) 
Burri et al. (IMPAMEL I) 
 
Trypanosomes in lymph, blood or CSF 
AND/OR 
> 50 WBC/µl CSF and twice that at previous 
evaluation OR 
20–49 WBC/µl CSF and symptoms of 
relapse (somnolence, long-lasting headache, 
recurrent fever)  
Burri et al. (2000); 
WHO (2000) 
 
Schmid et al. (IMPAMEL II) Relapse 
Trypanosomes in blood, lymph or CSF  
Suspected relapse  
> 50 WBC/µl CSF and twice that at previous 
evaluation OR 
WBC count is 6–49 cells/µl and clear 
symptoms attributed to relapse (somnolence, 
long-lasting headache, recurrent fever) 
Schmid et al. (2005) 
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Investigator Criteria References
 
Burri et al. 
(DB289) 
Relapse 
Trypanosomes in blood, lymph or CSF  
Suspected relapse  
> 50 WBC/µl CSF and twice that at previous 
evaluation OR 
WBC count is 6–49 cells/µl and clear 
symptoms attributed to relapse (somnolence, 
long-lasting headache, recurrent fever) 
Burri C, Schmid C, 
personal 
communication
  
Milord et al. (1992) Trypanosomes in the blood or CSF AND/OR  
≥ 50 WBC/µl CSF 
Milord et al. (1992)
 
Marion Merrel Dow, 
Eflornithine registration 
studies (1980/1990s) 
Trypanosomes in CSF AND/OR 
Obvious increase in CSF WBC count, CSF 
WBC above normal limits 
WHO/TDR and Aventis 
(2003)
 
Bisser S et al. Trypanosomes in the blood, lymph of CSF 
AND/OR 
> 20 WBC/µl CSF and at least twice that at 
previous evaluation AND/OR 
>20 WBC/µl CSF at 24 months after treatment 
Bisser S et al. (in press)
  
Pépin J, Milord F Trypanosomes in the blood or CSF AND/OR  
Cell count higher than previous count and ≥ 50 
WBC/µl CSF AND/OR 
Cell count higher than previous count, 20–49 
WBC/µl and recurrence of symptoms 
Pépin & Milord (1994)
 
Lourie EM Definition of significant increase/decrease in 
cell count: 
Initial count, 0–4: significant increase is to > 10 
Initial count, 5–20: significant increase is to 
more than double the initial count 
Initial count, > 20: significant reduction is to less 
than square root of the original 
Lourie (1942)
 
CSF: cerebrospinal fluid; HAT: human African trypanosomiasis; WBC: white blood cell 
 
2.2.3 Diagnosis of 'suspected relapse’ 
Some investigators have introduced a category of ‘suspected relapse’. This includes 
patients who show clinical symptoms of relapse, but in whom relapse could not be 
confirmed parasitologically. These patients may then undergo a pre-defined series of 
follow-up investigations before being diagnosed as confirmed relapses (see section  2.5). 
2.2.4 Diagnosis of cure 
Patients are classified as ‘cured’ if there is no evidence of relapse at the pre-determined 
time-point, in general, currently 24 months after treatment based on recommendations of a 
1986 WHO Expert Committee on Epidemiology and control of African trypanosomiasis 
(WHO Expert Committee on Epidemiology and Control of African Trypanosomiasis, 
1986). For the purposes of ongoing updates on efficacy evaluation in a patient group, 
patients who have not been diagnosed as relapsed at a certain time after treatment are 
classified as ‘cured at x months’ by some investigators. 
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Questions for discussion 
4 Why are different non-parasitological criteria used for determining relapse in the 
absence of trypanosomes in the CSF? 
5 What is the impact of different criteria for relapse in the absence of trypanosomes 
in the CSF in terms of comparability/assessment of the results of different clinical 
trials? 
6 What criteria for relapse should be applied on parasitologically unconfirmed 
CATT positive individuals who are considered as patients? 
7 Can one/should one agree on common non-parasitological criteria? 
2.3 Methodological issues 
2.3.1 Serological assessment 
The CATT is the only serological test applicable in field situations for screening of the 
population at risk for T. b. gambiense infection. As the sensitivity of the CATT depends 
on the variable antigen type of the circulating trypanosomes, performance may differ 
according to the geographical origin of the patients (Table A1.5). Sensitivity of the 
screening test on whole blood ranges between 83% and 100%, specificity between 78% 
and 97%. Specificity increases when CATT is performed on serum dilutions, a principle 
that is at the basis of determining subgroups of CATT-positives at risk, and of including 
the CATT end-dilution titre into the definition of a case. Two groups have reported that it 
has indeed been demonstrated that individuals with a CATT end-dilution titre of ≥ 1 : 16 
are at a high risk of having trypanosomiasis (Simarro et al., 1999; Chappuis et al., 2004).  
It has been reported that CATT cannot be used for follow-up since about half of the 
patients remain positive for up to 24–36 months after treatment (Paquet et al., 1992) and 
some patients even stay positive for up to 5 years after successful treatment (Miézan et al., 
2002). 
2.3.2 Parasite detection 
As all parasitological techniques rely on detection of the trypanosome, they should have 
100% specificity, assuming sufficient training of the personnel. 
The measured sensitivity of parasite detection tests depends on: 
• The detection limit of the respective test (Table A1.6); 
• Distribution of the parasitaemia; and 
• The choice of a gold standard. 
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Table A1.5   
Performance of CATT for diagnosis of HAT in different regions 
 
Test version Sensitivity 
(%) 
Specificity 
(%) 
Country Author 
CATT-whole blood ND 96.1 South Africa Bafort et al. (1986) 
CATT-whole blood 98.9–100.0 78.0–88.0 Democratic Republic of the 
Congo 
Pépin (1986) 
CATT-whole blood 83.3 96.8 Congo  Noireau et al. (1988) 
CATT-whole blood 91.7 92.5 Côte d'Ivoire Jamonneau (2001) 
CATT-whole blood 98.2 94.0 Central African Republic Truc et al. (2002) 
CATT-whole blood 100.0 96.7 Côte d'Ivoire  
CATT-whole blood 100.0 90.3 Côte d'Ivoire Magnus et al. (2002) 
CATT-whole blood 90.4 96.5 Uganda, Equatorial Guinea, 
Democratic Republic of the 
Congo 
 
CATT-whole blood 100.0 94.3 Cameroon Penchenier et al. (2003) 
CATT-serum 1:4 92.3 100.0 Caucasian, Democratic 
Republic of the Congo, Upper 
Volta, Côte d'Ivoire 
Magnus et al. (1978) 
CATT-serum 1:5 96.8 94.3 Congo  Noireau et al. (1988) 
CATT-serum 1:10 91.6 99.0 Congo  
CATT-serum 99.8 ND Côte d'Ivoire Miézan et al. (2002) 
CATT: card agglutination test for trypanosomiasis; HAT: human African trypanosomiasis; ND: not done 
 
Table A1.6:  
Detection limits reported for parasitological methods for the detection of HAT 
 
Technique
a 
 
Theoretical value 
(trypanosomes/ml) 
Reported detection limit 
(trypanosomes/ml) 
Lymph-node aspirate 50–100   
Fresh blood examination 100 6000–10000  
Thick blood film 40  600–5000  
Haematocrit
b
 centrifugation  
(Woo, 1971) 
15  500–600  
mAECT (Lumsden et al., 1979) 5  15–100  
QBC (Bailey & Smith, 1992) 15  15–300   (Ancelle et al., 1997)
c
 
Source: Adapted from Arbyn (1993)  
HAT: human African trypanosomiasis ; mAECT: mini-anion exchange centrifugation technique; 
QBC: quantitative buffy coat 
a
 References are for particular techniques developed by the given author 
b
 Erythrocyte volume fraction 
c
 Most recently reported detection limit  
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The theoretical detection limit of techniques for the detection of parasites in CSF 
depends on the volume of CSF that is examined. Ideally, one trypanosome per volume 
examined should be detectable by the concentration techniques. By direct examination of 
CSF, a maximum of 5 µl CSF is examined, corresponding to a detection limit of 200 
trypanosomes/ml. 
None of the existing trypanosome detection techniques is 100% sensitive. Evaluation of 
parasitological methods is hampered by the absence of a real gold standard and the 
reported diagnostic sensitivities differ according to the chosen reference tests (Table A1.7, 
Table A1.8). 
 
Table A1.7  
Diagnostic sensitivity of parasitological techniques for the detection of HAT in blood or 
lymph 
 
Author 
 
Lymph-
node 
aspirate 
(%) 
Fresh blood 
examination  
(%) 
Thick 
blood film  
(%) 
Haematocrit 
centrifugation  
(%) 
mAECT  
(%) 
QBC  
(%) 
Duvallet et al. (1979) 52 ND ND 86 ND ND 
Henry et al. (1981) 33 54 ND 82 ND ND 
Lumsden et al. (1981)
a
 ND ND 31 
63 
46 
73 
88 
100 
ND 
Dukes et al. (1984) ND 14 57 29 43 ND 
Molisho (1992) 25 ND 41 ND 93 ND 
Bailey & Smith (1992) 69 ND 93 ND ND 100 
Truc et al. (1994) 63 ND 100 44 80 93 
Miézan et al. (1994) 59 22 35 48 85 ND 
Truc et al. (1998) ND ND ND ND 100 85 
mAECT: mini-anion exchange centrifugation technique; HAT: human African trypanosomiasis; 
ND: not done; QBC: quantitative buffy coat  
a
 Two different methods to estimate sensitivity were used: (1) six patients known to be infected 
were repeatedly examined; (2) 35 mAECT-positives were examined by other techniques. 
 
Table A1.8    
Sensitivity of parasitological techniques for the detection of HAT in CSF 
 
Author 
 
Direct 
examination 
(%) 
Simple 
centrifugation 
(%) 
Double 
centrifugation 
(%) 
Modified simple 
centrifugation 
(%) 
Cattand et al. (1988)
a  
 ND 45 100 ND 
Miézan et al. (1994)
b 
 19 41 69 ND 
Miézan et al. (2000)
a 
 ND ND 82 97 
CSF: cerebrospinal fluid; HAT: human African trypanosomiasis; ND: not done 
a
 Gold standard is finding of trypanosomes in CSF 
b
 Gold standard is finding of trypanosomes in any body fluid 
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For diagnosis, any of the parasitological techniques is valid (although higher sensitivity 
can be expected using concentration techniques). From the above tables it is, however, 
clear, that for assessment of the disease stage and cure in clinical trials, concentration 
techniques are more appropriate.  
Owing to the interplay between parasite antigenic variation and the patient’s immune 
system, the numbers of parasites in the blood of the patient may vary considerably. As a 
consequence, the parasite concentration may remain under the detection limit at certain 
moments, while at other moments parasites can be easily detected. In case of high 
suspicion of infection or relapse, it is advisable to repeat parasitology on different 
occasions if trypanosomes cannot be detected immediately. 
In the reality of field use, the sensitivity and specificity of the parasite detection depends 
not only on the method used (e.g. single or double centrifugation) but also on the level of 
training of the personnel (e.g. centrifugation technique, handling of samples, 
differentiation of trypanosomes from microfilarial worms) and the quality of the 
equipment (e.g. microscopes, other laboratory equipment). 
Questions for discussion 
8 Can we/do we need to agree on common methods for inclusion criteria and 
efficacy parameter assessment for the purpose of clinical trials? 
2.4 Potential surrogate markers for cure/relapse  
2.4.1 Currently available data on surrogate end-points 
A few alternative markers for follow-up of patients are suggested in the literature, mainly 
IgM and trypanosome-specific antibody in CSF.  
Already in 1967, Mattern had observed that relapses are always accompanied or even 
announced by an increase of IgM in the serum as well as in the CSF (Mattern, 1967). 
According to Knobloch et al. (1984), “efficacy of treatment is indicated by a decrease of 
IgM in CSF, CSF total protein, and probably CSF trypanosome specific antibody”. 
Greenwood & Whittle (1973) state that “a fall in CSF IgM follows successful treatment, 
but it may be weeks or months before normal levels are obtained”.  
A more detailed illustration of the evolution of IgM in CSF is shown in Whittle et al., 
1977, according to whom the measurement of IgM in the CSF is of great help in diagnosis 
and management. Although they observed that IgM levels decrease slowly to normal by 
12 months after treatment, a high level at that time or a rise after treatment are described 
as helpful in diagnosing relapsed patients. Moreover, they state that at any time after 
treatment, absence of IgM in a patient with a high CSF protein and raised cell count 
should cast doubt on the diagnosis of relapse. 
It has been described that antibodies in the CSF drop quickly after successful treatment 
and the decrease of trypanosome-specific antibody concentrations in CSF has been 
proposed as an interesting parameter for definite cure (Roffi et al., 1979; Knobloch et al., 
1984; Smith et al., 1989). This was confirmed more recently in a large group of patients 
infected with T. b. gambiense in Côte d’Ivoire (Miézan et al., 2002). Relapses in this 
group were characterized by the presence of trypanosome-specific antibodies. 
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From the same data, it has been reported (Cross & Jaffar, 2003) that in multivariate 
analysis, the presence of antibody in CSF measured at discharge was associated 
significantly with any relapse. Protein in CSF above the medial level of 36 mg/l was 
associated with relapse within 12 months of discharge, as was the presence of antibody in 
the CSF. At 12 months, a WBC count of > 50 WBC/µl CSF and antibody end-dilution 
titre of ≥ 2 were associated independently with relapse beyond 12 months. 
Thus, although literature on surrogate markers for follow-up is scarce, promising 
alternative parameters have been suggested for assessment of cure or relapse, but have not 
found their way to the field. This might be owing to the lack of field-adapted tests. 
The recent development of some field-adapted tests for assessment of disease stage and 
cure could change this situation. 
• Based on the occurrence of a strong predominant intrathecal IgM synthesis in second-
stage T. b. gambiense patients (Lejon et al., 2003), an experimental agglutination test 
for detection of IgM in the CSF, LATEX/IgM, was developed (Lejon et al., 2002). 
The reagent consists of anti-human IgM monoclonal antibodies covalently coupled to 
stained latex particles. Reagent and CSF are mixed on a card and rotated for 5 
minutes. The presence of IgM is revealed by macroscopic agglutination. When testing 
serial dilutions of the CSF, an end-titre (highest dilution factor still giving a positive 
reaction) is obtained, which gives an estimate of the concentration of IgM in the CSF. 
• LATEX/T. b. gambiense is an antibody-detecting agglutination test (Büscher et al., 
1999). The reagent consists of semi-purified variable antigens of T. b. gambiense 
covalently coupled to latex particles in suspension. Although the test was developed 
for use on serum or blood, it can be applied on CSF. The reagent is mixed with the 
CSF on a card and rotated. The presence of trypanosome-specific antibodies is 
revealed by macroscopic agglutination. 
Both tests remain to be validated on a large scale. 
Other recent developments include: 
• A dot–blot method to detect anti-neurofilament and anti-galactocerebroside antibodies 
in the CSF of patients with trypanosomiasis shows promising initial results for staging 
of the disease, but remains to be further evaluated (Courtioux et al., 2003). No data 
about the usefulness of these types of antibodies for follow-up are available yet. 
• Patients with second-stage T. b. gambiense human African trypanosomiasis show a 
disruption of the 24-hour sleep–wake distribution with the abnormal occurrence of 
sleep-onset rapid eye movement (SOREM). This can be recorded by 
polysomnography, which could represent a non-invasive method to detect parasite 
invasion in the brain (Buguet et al., 2004). 
• Different PCR assays exist, but none of them are yet validated for diagnostic purposes 
(Schares & Mehlitz, 1996; Kabiri et al., 1999; Jamonneau et al., 2001; Welburn et al., 
2001; Radwanska et al., 2002). In principle, PCR can be used for any patient’s sample 
that may contain trypanosome DNA, like whole blood or the buffy coat, lymph-node 
fluid or CSF, but results are not always unequivocal. 
  46 
2.4.2 Validation of surrogate end-points 
In view of the variable current criteria for relapse, the high number of cases lost-to-
follow-up, the lumbar punctures needed during follow-up and the long follow-up period, 
additional studies are required on: 
• Methodological improvement of cell count and trypanosome detection, and definition 
of cell count-related relapse criteria based on scientific evidence; 
• New follow-up criteria; 
• The combination of new and existing follow-up parameters.  
Table A1.9 summarizes some studies and trials (ongoing or planned for the near future) 
involving analysis of CSF samples obtained during patient follow-up in order to detect 
relapses after treatment via potential surrogate markers of relapse. 
 
Table A1.9   
Studies and trials involving laboratory analysis of follow-up samples of CSF 
 
Activity Investigator Country Analyses Status 
Retrospective 
study on 400 
patients 
Institute of 
Tropical 
Medicine 
Democratic 
Republic of 
the Congo  
CSF IL-10, CSF IgM, CSF-
specific antibody, CSF protein, 
etc 
Analyses 
started 
Prospective study 
on 500 patients 
Institute of 
Tropical 
Medicine 
Democratic 
Republic of 
the Congo  
CSF IL-10, CSF IgM, CSF-
specific antibody, CSF protein, 
etc 
Start of study 
in September 
2004 
DB-289 trial Swiss 
Tropical 
Institute 
Democratic 
Republic of 
the Congo 
CSF IgM Ongoing 
Clinical trial of 
eflornithine-
nifurtimox 
Médecins 
Sans 
Frontières/ 
Epicentre 
Congo CSF IgM Ongoing 
CSF: cerebrospinal fluid; IgM: immunoglobulin; IL: interleukin 
 
Questions for discussion 
9 Are the ongoing and planned studies sufficient for the validation of these new 
tests? If not, what types of additional field trials are needed? 
10 What is the present and future role of these new tests for staging of HAT and 
diagnosis of relapse in clinical trials? 
2.5 Patient evaluation for relapse/cure in clinical trials 
Patients are evaluated for treatment efficacy in general at the EoT and at different times 
after treatment. Most frequently the targeted follow-up time-points are 6, 12, 18 and 
24 months after treatment. Since the direct or surrogate markers for relapse and decision 
on rescue treatment include CSF parameters (trypanosomes, WBCs, potentially IgM or 
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trypanosome specific antibodies), a lumbar puncture has to be performed at follow-up. 
For many patients, fear of the lumbar puncture for different reasons is a significant 
deterrent for attending follow-up investigations, in particular if they are feeling well. 
If trypanosomes are detected in the blood, lymph or CSF, diagnosis of relapse is 
unambiguous. Further follow-up of patients is required for the patients’ health, but from a 
clinical trial point of view, the end-point has been reached. 
For patients who are suspected to have relapsed based on WBC counts, immunodiagnostic 
parameters or signs and symptoms of disease, different algorithms for follow-up may be 
used by different investigators and these have implications for the time that relapse is 
diagnosed and consequently for the time the rescue treatment is initiated. All 
methods/algorithms for follow-up and diagnosis of relapse include lumbar punctures. 
Algorithms for follow-up of patients in clinical trials include (Burri C, personal 
communication; TDR protocol, in preparation): 
• Suspicion of relapse based on WBC counts: 
 If there is at any follow-up examination an increase of the WBC count in the 
CSF of greater than 10 cells/µl, a test repetition (including microscopic 
examinations of lymph-node aspirate and blood) will be done 1 month later. 
 If at test repetition no trypanosomes are detected and there is no further 
increase of the CSF WBC count, the patient will be asked to return for 
additional testing on a 3-monthly basis. 
 If at any follow-up examination no trypanosomes are detected and there is a 
further increase of the CSF WBC count that cannot be explained by another 
likely diagnosis, the patient will be considered as a suspected treatment 
failure and treated as per the planned rescue treatment in the protocol. 
 If parasites are detected at any follow-up examination, the patient will be 
considered as a confirmed treatment failure. 
Immunodiagnostics may be used during follow-up for the identification of patients who 
require particular attention. The basic algorithm is the same as used for follow-up of 
patients suspected to have relapsed based on CSF WBC count (Burri C. personal 
communication). 
• Suspicion of relapsed based on immunodiagnostic test results: 
 If there is at least a fourfold increase in the CSF-end-dilution titre of 
LATEX/IgM test compared with the post-treatment value or the preceding 
follow-up value, a test repetition (including microscopic examinations of 
blood and lymph-node aspirate) will be done 1 month later. 
 If at test repetition no trypanosomes are detected and there is no further 
increase in the end-dilution titre, the patient will be asked to return for 
additional testing on a 3-monthly basis. 
 If at test repetition no trypanosomes are detected but there is a further 
increase of the end-dilution titre of the test, the patient will be considered as 
a suspected treatment failure and treated as per the planned rescue treatment 
in the protocol. 
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 If parasites are detected at any follow-up examination the patient will be 
considered as a confirmed treatment failure. 
Questions for discussion 
11 Can we agree on a common definition of who is suspected to have relapsed and 
who should undergo intense follow-up investigations? 
12 What follow-up investigations should be performed on patients suspected to have 
relapsed? Can we / should we agree on a common algorithm? 
13 Can we minimize the number of lumbar punctures during follow-up without 
jeopardizing patient safety? 
3. HAT-specific challenges for the clinical evaluation of a new 
treatment modality 
The conduct of clinical studies in patients with HAT faces several difficulties which are 
rarely encountered simultaneously in clinical trials for other tropical diseases, and never 
in non-tropical diseases of the developed countries. These include: 
• The areas in which the disease is endemic, which are characterized by, for example, 
remoteness, extreme poverty and lack of, for example, transport and health care 
infrastructure; 
• Lack of availability of sites suitably equipped and staffed for clinical trials; 
• The usually very low endemicity even in identified disease foci, the slow disease 
development and the totally unspecific signs and symptoms of the disease which 
require a very large number of patients to be screened to identify patients; 
• Elimination of the patient base within a reasonable distance from the site within a 
few years of the initiation of a new treatment site as a consequence of the successful 
treatment of the infected population in the vicinity of the site; 
• A long follow-up period until efficacy can be ascertained (24 months after treatment 
according to currently accepted standards); 
• A high loss to follow-up due to a combination of: 
 lack of transport infrastructure for the patients; 
 extreme poverty; 
 high mobility of the population even in areas without civil unrest; 
 high probability of political instability/civil unrest in some areas; 
 the long treatment follow-up required; and 
 patients’ fear of the lumbar puncture at follow-up, especially among patients 
who do not experience signs and symptoms of the disease. 
This section summarizes some of the data needed for discussion on how best evaluate the 
efficacy and safety of a new treatment modality under these conditions. 
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3.1 Requirements for build-up of clinical trial sites 
In general, two independently conducted clinical studies, both powered for suitable 
statistical significance, are regarded as necessary to establish the efficacy and safety of a 
new treatment and, if applicable, its superiority or non-inferiority relative to the standard 
of care. For treatments with cure rate of ≥ 90% or a relapse rate of ≤ 10%, each of these 
studies needs to enrol sufficient patients to obtain several hundred patients who can be 
evaluated for drug efficacy. 
Currently there are very few sites equipped and staffed to conduct clinical trials according 
to good clinical practice (GCP) for HAT. The implementation of a new clinical trial 
centre for trypanosomiasis includes significant improvement of the facility. This includes 
usually construction or structural improvement for the laboratory and patient 
accommodation and most often electrical installations. Often the equipment for the 
routine examinations is old and outdated, and all equipment linked to the study must be 
added. The laboratory staff needs to be re-trained in basic parasitological techniques, and 
to be introduced to all other methods (e.g. biochemistry, haematology). The nursing and 
laboratory staff has to undergo introduction to the principles of clinical trials including 
GCP training. The medical staff very often needs additional training in the observation 
and classification of symptoms and signs. 
Mobile teams (i.e. a vehicle with a team of about eight people, which circulates in the foci 
identified) are critical for the conduct of a clinical trial, since only the use of active case 
search will normally yield sufficient patient numbers. Most national plans foresee the 
activity of mobile teams for active case search, but very often those structures do not exist 
or are only partially functional. Existing mobile teams must be appropriately trained and 
equipped with a lot of effort before the initiation of a trial. 
It must be understood that the staff in rural centres is generally very limited and very often 
there is no physician, which implies further challenges for the conduct of clinical trials: 
first, it may be difficult to find additional staff to relocate and work under the given 
circumstances; and second, all developments need to be made in a sustainable way, to 
allow a durable improvement in diagnostic and treatment capacity. 
Consequently, the conduct of two independent pivotal trials for the evaluation of the 
safety and efficacy of a new treatment modality for HAT is a major challenge and may 
not actually be feasible. 
3.2 Identification of patients for clinical trials of new treatment modalities 
The clinical trial-initiated and/or accelerated screening and treatment activities will lead to 
efficient detection and treatment of patients and thus to the elimination of the ‘patient 
reservoir for the trial’. Therefore, the same site can rarely be used for larger studies for 
more than 1 to 2 years in a row. 
Table A1.10 and Figure A1.1 demonstrate that there has been a decrease by a factor of 30 
in the numbers of detected cases within 6 years as a consequence of active case detection 
and treatment in the North Equatorial province of the Democratic Republic of the Congo. 
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Table A1.10 
Screening and case detection for HAT in a control programme in an endemic zone in the 
Democratic Republic of the Congo 
 
Screening and case detection 1997 2003 
Population screened 286 919 949 747 
New cases (n) detected 14 764 1 597 
New cases (%) of people screened 5.14 0.17 
HAT: human African trypanosomiasis  
Source: N'Siesi (2004)  
 
 
Figure A1.1 
Population screened and new cases of HAT detected between 1998 and 2003 in North 
Equatorial Province of the Democratic Republic of the Congo 
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HAT: human African trypanosomiasis; TP: Total population screened, NC: new cases detected 
Source: N’Siesi (2004)  
Even in newly identified disease foci, the endemicity of HAT is usually very low. This, 
together with the slow disease development and the totally unspecific symptoms and signs 
of HAT, in particular in its first stage, requires screening of a very large number of 
patients for enrolment to clinical trials. 
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Table A1.11 
Number of patients screened and included in a trial of drugs to combat first-stage HAT 
 
No. of patients screened and 
included 
Viana 
(Angola) 
Maluku 
(Democratic 
Republic of the 
Congo) 
Vanga 
(Democratic 
Republic of the 
Congo) 
Total No. of persons screened  10 451 31 491 12 253 
Total No. of new cases identified (%) 62 (0.59%) 298 (0.95%) 65 (0.53%) 
New cases, first stage 6 115 31 
Cases included (%) 4 (0.04%) 28 (0.09%) 15 (0.12%) 
Cases excluded owing to  5
a
 88
a
 16 
 Age 3 27 10 
 Weight — 14 3 
 Abnormal ECG 2 11 — 
 Other reasons 0 36 3 
Source: Burri C, personal communication
  
ECG: electrocardiogram; HAT: human African trypanosomiasis 
a
 Not complete agreement because additional patients were included from passive reporting to centre 
3.3 Time of relapse in recent disease control treatment programmes and clinical 
studies 
The currently accepted standard follow-up time for efficacy for patients treated for late 
stage HAT is 24 months after treatment. Eflornithine was approved in the USA based on 
data from 282 treated patients, including 49 patients with ≥ 2 years of follow-up (all 
cured), 80 with 12–23.5 months of follow-up and 64 with 3–11.5 months of follow-up. 
Eflornithine was approved in France based on data from 556 treated patients, including 
114 with ≥ 2 years of follow-up and 103 with 12–23.5 months of follow-up (Marrion 
Merrel Dow, 1988). 
Under the conditions under which clinical trials in HAT patients have to be conducted, 
obtaining follow-up for a significant fraction of the patients requires ‘active’ follow-up 
(i.e. mobile teams of appropriately trained personnel travelling out to find and evaluate 
the patients). The longer the follow-up time, the more effort needs to be invested into the 
follow-up and the lower the probability of obtaining complete follow-up data (for details 
see section  3.4). Thus, it is worthwhile to review the data available on the time of detected 
relapse to evaluate whether 24 months after treatment is the only time or the best time at 
which to assess the efficacy of a new treatment modality. 
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3.3.1 Relapse of patients with first-stage HAT  
Relapses after suramin 
Suramin is the drug of choice for first-stage T. b. rhodesiense infection. Cure rates of over 
95% have been reported (Apted FIC, 1980), but also high failure rates in the range of 25–
35% (Neujean, 1950; Veeken et al., 1989). Initially, suramin was also used against 
T.  b .gambiense, with a very high efficacy (Harding, 1945), but today suramin is no 
longer used for T. b. gambiense infection except in combination with pentamidine. The 
combination of suramin plus pentamidine was considered to be less toxic than 
monotherapy and to cause fewer relapses (Williamson, 1970). However, Pepin & Khonde 
(1996) question the usefulness of the combination of two drugs which are known to 
penetrate very poorly into the central nervous system. They reported that in vitro a drug 
exposure of 1 µg/ml for 24 hours is sufficient to inactivate the bloodstream forms. 
It is not known whether suramin-resistant T. b. gambiense or T. b. rhodesiense strains 
exist today. Observed relapses could be attributed to second-stage infections, which were 
not diagnosed as such. Since it is known that suramin penetrates very poorly into the 
central nervous system, this drug is not expected to cure a second-stage infection at the 
doses used in humans. 
Relapses after pentamidine 
The reported relapse rates after a course of five injections were all in the same range of 
approximately 7% (Jonchère, 1951; Dutertre & Labusquiere, 1966). Such relapses could 
be explained by second-stage infections, which were misdiagnosed as first-stage, rather 
than by pentamidine-refractory HAT/pentamidine-resistant trypanosomes, which have not 
been described so far in the field. Neujean & Evens (1958) reported that 16% of 
pentamidine-treated patients relapsed, but could subsequently be cured with melarsoprol. 
Small amounts of pentamidine corresponding to 0.5–0.8% of the plasma concentrations 
were found in the CSF of all patients after the last dose of a 10-day treatment course. It 
has been reported (Bronner et al., 1991; Bronner, 1994) that pentamidine generally 
persisted in CSF for at least 30 days. In vitro, concentrations as low as 10 ng/ml have a 
trypanocidal effect during prolonged exposure (Miézan et al., 1994b). On the basis of 
these results, the use of pentamidine for so-called early–late-stage patients with a WBC 
count of up to 20 cells/mm
3
 instead of 5 cells/mm
3
 was proposed (Doua et al., 1996). In a 
preliminary study, a small number of patients was treated accordingly to the new 
definition. Although the rate of relapse after pentamidine treatment was slightly higher 
than after treatment with melarsoprol (6% versus 3.7%), the new definition is now in use 
as a standard in Angola; and publication of the results is pending.  
Table A1.12 summarizes the data on time of relapse of patients diagnosed as early-stage 
and treated with pentamidine in the Médecins Sans Frontières treatment programme in 
Arua, Uganda, with active follow-up. The overall relapse rate, calculated based on the 
number of patients discharged alive was 7.1%. Among the 26 patients who were 
diagnosed as relapsed, 25 patients were staged after relapse as stage 2. 
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Table A1.12 
Time of at which relapse was diagnosed in MSF treatment programme for first-stage HAT in Arua, Uganda, 1995–2000 
 
Programme Treated 
(treatment) 
Discharged alive Treated 
≥ 24 
months 
before 
data 
cut-off 
Patients diagnosed as relapsed, by months after treatment 
(% of total relapsed) 
Reference 
    Total ≤ 6 ≤ 11.5 12–17.5 18–23.5 ≥ 24  
Active follow-up
a
          
Control 677 
(pentamidine) 
675 675 48
a
 5 (10) 9 (19) 16 (33) 8 (16.7) 15 (31) Priotto G, personal communication 
(11 August 2004) 
HAT: human African trypanosomiasis; MSF: Médecins Sans Frontières 
a
 Includes two patients who died during follow-up independent of cause of death 
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3.3.2 Relapse of patients with second- stage HAT  
Table A.1.13 summarizes data on the time of diagnosis of relapse from field treatment 
protocols and clinical studies. The relapses at different times after treatment are quantified 
as percentage of total number of patients diagnosed as relapsed. 
Studies/programmes with active follow-up are listed separated from those with passive 
follow-up. For active follow-up, patients were actively sought out for follow-up 
examinations. For passive follow-up, no specific efforts were undertaken to reach patients 
for follow-up, so that under-diagnosis of early relapses as well as diagnosis of total 
relapses are less accurate than in studies with active follow-up. Consequently, studies with 
active follow-up provide a more accurate database for assessment of the time of relapse 
after treatment. 
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Table A1.13   
Time at which relapse was diagnosed in control programmes and clinical studies on second-stage HAT 
 
Programme Treated 
(treatment) 
Discharged 
alive
c
 
Treated ≥ 24 
months before 
data cut-off 
Patients diagnosed as relapsed, by months after treatment 
(% of total relapsed)
a,b
 
Reference 
    Total ≤ 6 ≤ 11.5 12–17.5 18–23.5 ≥ 24  
Active follow-up
d
          
Control/clinical 
studies 
1557
e
 
(different, see 
footnote e) 
1530 1530 406 131 (33) 252 (62) 93 (25) 26 (6) 35 (9) Priotto 
(2004) 
 1422 new cases 
(melarsoprol) 
1363 1363 398 69 (17) 224 (56) 96 (24) 35 (9) 43 (11) 
 
Control  1402 
(melarsoprol) 
1402 900 26
f
 0–9 months 
19 (73) 
9–18 months 
5 (19) 
18–30 months 
2 (8) 
Chappuis 
(2004)
 
Control 587 
(eflornithine) 
573
g
 111
g 
25 10 (40) 22 (88) 3 (12) Franco et al. 
(2004)
 
Clinical study 
(Impamel I)
h
 
500 
(melarsoprol) 
483 483 25 8 (32) 12 (48) 6 (24) 5 (20) 2 (8) Schmid et al. 
(2004)
 
Passive follow-up
h
         
 
Treatment
i
 Not available 
(melarsoprol) 
812 812 32 16 (50) 16 (50) 8 (25) 7 (21.9) 1 (3.1) Cross & 
Jaffar (2003)
 
Field study 
(Impamel II) 
2571 
(melarsoprol) 
2423 2423 179 115 (64) 162 (91) 10 (6) 3 (2) 4 (2) Schmid 
(2004)
 
HAT: human African trypanosomiasis
  
a 
Includes patients who relapsed ≤ 6 months after treatment 
b 
Relapsed patients includes patients who died during follow-up, irrespective of the cause of death. 
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c 
Discharged alive, excluding deaths shortly after discharge d Studies/programmes with active follow-up are separated from those with passive follow-up. For 
active follow-up, patients were actively sought out for follow-up. For passive follow-up, no specific efforts were undertaken to reach patients for follow-up, so 
that underdiagnosis of early relapses and total relapses are less accurate than in studies with active follow-up. 
e 
Patients included received melarsoprol treatment (after prior relapse), eflornithine for 7 days, eflornithine for 14 days, nifurtimox-melarsoprol combination, 
nifurtimox-eflornithine, melarsoprol-eflornithine.
 
f 
Relapses among 900 patients who completed all scheduled follow-up investigations at 6, 12 and 24 months. 
g 
Patients who completed treatment and were discharged. At the time of data cut-off for this analysis, 503 patients had been treated at ≥ 6 months, 423 
patients at ≥ 12 months and 111 patients at ≥ 24 months before data cut-off. Relapse rates were 10/503 in the 6 months after treatment, 21/423 6–12 months 
after treatment and 14/111 during 13–24 months after treatment. 
h 
The high number of patients diagnosed as relapsed in the second year after treatment is attributed to underdiagnosis during the first year and efforts to 
follow up all patients in the second year who had not been seen during the first year after treatment. 
i 
All relapses reported for the period of 12–17.5 months were diagnosed at around 12 months after treatment.
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Data on time of relapse determined by HATSENTINEL
4
 from three different sites in the 
Democratic Republic of the Congo are shown in Figure A1.2. These hospitals do some 
active follow-up. However, the majority of patients were diagnosed as relapsed when they 
came to the clinic on their own initiative. 
 
Figure A1.2   
Time of relapse detection among 371 patients diagnosed as relapsed within the 
HATSENTINEL in East Kasai Province of the Democratic Republic of the Congo 
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Source: Data generated by HATSENTINEL 
For interpretation of the data in Table A1.13, it needs to be kept in mind that for all those 
data sets where the number of patients treated is larger than the number of patients with at 
least 24 months passed since treatment, there is some bias towards relapses earlier on after 
treatment, since the number of patients who completed the specified period of time after 
treatment (and thus contributed to relapses at that time-point) is the smaller, the later after 
treatment it is. This bias is increased when the percentage of patients seen for follow-up 
decreases with increasing time between treatment and follow-up.  
                                                 
4
 HATSENTINEL is a network to monitor treatment failure and drugs resistance for HAT. It was 
implemented in July 2002 and continues as of October 2006. It was developed by the Centers for Disease 
Control and Prevention (CDC), Division of Parasitic Diseases, National Center for Zoonotic, Vector-borne 
and Enteric Diseases, Coordinating Center for Infectious Diseases. CDC is a WHO Collaborating Centre for 
Surveillance of Human African Trypanosomiasis, Treatment Failure, and Drug Resistance. The 
HATSENTINEL sentinel surveillance network consists of nine sites to date; seven sites are located in areas 
endemic for T. b. gambiense (Angola, Democratic Republic of the Congo, Sudan) and two sites are in areas 
endemic for T. b. rhodesiense (Uganda, United Republic of Tanzania) 
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Table A1.14 provides more information on follow-up data available for the data in 
Table A1.13. 
On the other hand, in the IMPAMEL I study (Schmid et al., 2004), specific follow-up 
efforts during the second year after treatment for patients who had not presented for 
follow-up during the first year, may have resulted in relapses that occurred during the first 
year after treatment being diagnosed and recorded only during the second year. This 
would result in a bias towards relapses later on after treatment: nine patients diagnosed as 
relapsed 12–24 months after treatment had had either no previous follow-up examination 
or the previous follow-up examination was more than 10 months ago. 
Because of the environment in which HAT is endemic and the nature of the disease, it is 
not possible to make assumptions regarding the fate of patients not seen for follow-up—
patients may be cured and thus do not see the necessity to invest what may be 
considerable resources for them into a visit to the treatment centre and to have to undergo 
lumbar puncture or may have relapsed and be unable (physically and/or financially) to 
visit the treatment centre. 
Within these limitations, the data in Table A1.13 do suggest that between 70% and 90% 
of relapses occur within 18 months after treatment, and between 40% and 90% of relapses 
occur already within 12 months after treatment. 
3.4 Follow-up of HAT patients 
Experience over the past 20 years has shown that under the conditions in which 
treatment/control programmes and clinical studies for HAT are conducted, follow-up of 
patients as per protocol (in clinical studies and nongovernmental organization-conducted 
treatment programmes, typically 6, 12, and 24 months after treatment; in other control 
programmes, ideally at least once at 24 months after treatment) is always incomplete. 
Table A1.14 summarizes published and unpublished data on follow-up of first- and 
second-stage HAT patients. 
In the tables, the number of patients seen for follow-up relative to the number of patients 
expected to be seen for follow-up was quantified, i.e. all patients who were discharged 
alive, whose follow-up was due at the time-point specified and who had not relapsed or 
died before the time-point specified. 
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Table A1.14   
Follow-up rates in control programmes and clinical studies on HAT 
 
Programme Treated  
(treatment) 
Country Follow-
up 
Patients seen for follow-up/patients expected for 
follow-up (patients seen as % of patients expected)
a
 
Reference 
 
    ≤ 11.5 
months 
12–17.5 
months 
18–23.5 
months 
≥ 24 
months 
 
Active follow-up
b
       
 
Control 638 
(pentamidine) 
Sudan (Yei) Active 389/509 
(76) 
218/354 
(26) 
Not available 19/70 
(26) 
Franco et al. (2004) 
 
Treatment 
programme 
732 
(pentamidine) 
Uganda (Arua) Active 626/727 
(86) 
10–18 
months 
576/716  
(80) 
> 18 months 
523/692 
(76) 
Priotto G, personal communication 
(Epicentre database, introduction to 
briefing document, 11 August 2004) 
 
Control 760 
(pentamidine) 
Sudan  
(Kiri) 
Active 3–9 months 
500/760 
(66%) 
9–18 months 
364/748 
(49%) 
18–30 months 
216/740 
(29%) 
Chappuis F, personal 
communication, 16 August 2004
 
Control/clinical 
studies 
1422 
(melarsoprol, new 
cases) 
Uganda (Arua) Active 0–9 months 
1149/1345 
(85) 
10–18 
months 
919/1175 
(78) 
> 18 months 
748/1048 
(71) 
Priotto, G (Epicentre), 8 July 2004 
Control/clinical 
studies 
825 
(melarsoprol, 
eflornithine, 
nifurtimox) 
Uganda (Arua) Active 0–9 months 
628/756 
(83) 
10–18 
months 
463/585 
(79) 
> 18 months 
390/493 
(79) 
Priotto G, personal communication 
(Epicentre database, introduction to 
briefing document, 11 August 2004) 
 
Control 1402 
(melarsoprol) 
Sudan  
(Kiri) 
Active 3–9 months 
830/1288 
(64.4) 
9–18 months 
549/1173 
(46.8) 
18–30 months 
267/900 
(29.7) 
Chappuis (2004) 
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Programme Treated  
(treatment) 
Country Follow-
up 
Patients seen for follow-up/patients expected for 
follow-up (patients seen as % of patients expected)
a
 
Reference 
 
    ≤ 11.5 
months 
12–17.5 
months 
18–23.5 
months 
≥ 24 
months 
 
Control 587 
(eflornithine) 
Sudan  
(Yei) 
Active 405/503 
(80.5) 
284/413 
(68.8) 
Not applicable 45/100 
(45.0) 
Franco et al. (2004) 
 
Clinical study 
(Impamel I) 
500 
(melarsoprol) 
Angola Active 413/483 
(85.5) 
12–23.5 months 
301/463 (65.0) 
 
60/426 
(14.1) 
 
Schmid et al. (2004) 
 
Mixed active–passive follow-up      
 
Field study 
(Impamel II)
b
 
2571 
(melarsoprol) 
See below Mixed 1089/2423 
(45) 
264/2245 
(12) 
55/2235 
(2.5) 
29/2233 
(1.3) 
Schmid (2004) 
 
 651 Sudan – IMC Active? 338/627 (54) 33/507  
(7) 
8/492 (2) 0  
 23 Equatorial 
Guinea 
Active 15/21  
(71) 
9/18  
(50) 
10/18  
(56) 
4/18  
(22) 
 
 504 Sudan (Kiri) Active 304/480 (63) 123/457  
(27) 
15/456  
(3) 
20/456  
(4) 
 
 30 Central African 
Republic 
Unknown 28/29  
(97) 
26/28  
(93) 
0 0  
 27 Côte d'Ivoire Unknown 25/25  
(100) 
6/24  
(25) 
0 0  
 547 Angola Passive 58/515  
(11) 
0 0 0  
 561 Democratic 
Republic of the 
Congo 
Passive 191/516 
(37) 
62/509  
(12) 
21/500  
(4) 
4/500  
(1) 
 
 228 Congo Passive 126/210 
(60) 
2/192  
(1) 
0 1/192  
(1) 
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Programme Treated  
(treatment) 
Country Follow-
up 
Patients seen for follow-up/patients expected for 
follow-up (patients seen as % of patients expected)
a
 
Reference 
 
    ≤ 11.5 
months 
12–17.5 
months 
18–23.5 
months 
≥ 24 
months 
 
         
Passive follow-up
b
       
 
Treatment Not available, 
discharged 812 
(melarsoprol) 
Côte d'Ivoire Passive 429/812 
(52.8) 
345/812 
(42.5) 
276/812 
(34.0) 
279/812 
(34.4) 
Cross & Jaffar (2003) 
 
HAT: human African trypanosomiasis; IMC: International Medical Corps  
a
 Excludes patients who died during treatment or shortly after treatment. 
b
 Studies and programmes with active follow-up are separated from those with passive follow-up. For active follow-up, patients were actively sought for follow-
up examinations.  
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The data in Table A1.14 show that even in nongovernmental-organization treatment 
programmes or clinical studies with active patient follow-up, follow-up rates drop 
significantly with time since treatment. 
3.5 Calculation of efficacy 
Efficacy in studies of infectious diseases is usually quantified as the number of patients 
that fulfil the pre-defined criteria for ‘treated successfully’ or ‘treated unsuccessfully’ as a 
percentage of: 
(a) all patients who received at least one dose of study medication (‘intent-to-
treat’ population); 
(b) all patients who received treatment as prescribed by the protocol (‘per-
protocol’ population). 
Data on whether or not a patient fulfils the criteria for ‘treated successfully’ or ‘treated 
unsuccessfully’ are expected to be available for the vast majority of patients treated in the 
‘intent-to-treat’ population and the ‘per-protocol’ population (population that can be 
evaluated for treatment efficacy). 
In most studies of infectious disease, the time of follow-up required until the 
determination of successful or unsuccessful treatment is only a few weeks. This 
contributes to making it possible to have the required data for the complete or nearly 
complete ‘intent-to-treat’ and ‘per-protocol’ populations. 
The data in Table A1.14 show that for HAT patients it is not possible to achieve close to 
100% follow-up at any time after treatment and that follow-up rates drop with time after 
treatment. Thus, the choice of timing for determination of the nominator and of an 
appropriate denominator for accurate absolute and relative quantification of efficacy of a 
new treatment modality for HAT is a major issue. 
 
Questions for discussion 
14 The data in Table A1.13 show that the majority of patients who relapse within 
24 months after treatment do so within the first 12 to 18 months. The data in Table 
A1.14 show that even with active follow-up it is in most cases impossible to 
obtain 24 months follow-up on > 80% of patients. 
(a) Is final efficacy assessment at 12 or 18 months sufficient to assess the 
value of a new treatment modality in a pivotal trial? Can a final efficacy 
assessment at 12 or 18 months improve the reliability of the efficacy 
quantitation because data are based on a higher percentage of patients 
evaluated? 
(b) What additional value for the assessment of efficacy of a new treatment 
modality is provided by 24 months follow-up data? 
(c) For dose finding or proof of concept studies, a 24 months follow-up 
period is not realistic. What types of efficacy data provide an adequate 
basis for deciding on a pivotal study and the dose to be evaluated in it? 
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15 If a significant percentage of patients are lost to follow-up, this creates uncertainty 
as to how cure and relapse rates should be calculated. This situation is further 
complicated by the fact that most of the patients with follow-up data at one time-
point are not available for follow-up at another time-point, and that some patients 
may not consent to a CSF sample being taken (the pre-requisite for parasitological 
confirmation of cure/relapse) at each or any follow-up time-point. This makes 
comparison of cure or relapse rates at different times after treatment difficult, 
since (i) the numerator is based on different patient populations; and (ii) the 
denominator, if calculated as the number of patients with follow-up data, differs 
between follow-up time-points. Furthermore, comparison between treatment arms 
of the study is complicated if the percentage of patients with follow-up data differs 
substantially between treatment arms. 
16 Denominator for relapse and cure rates: is the number of patients discharged alive 
a better (more consistent) denominator for cure or relapse rates than the traditional 
‘number of patients with follow-up data’? 
17 Primary efficacy variable:  
(a) Is the parasitologically confirmed treatment failure rate, calculated as 
follows, a suitable primary efficacy variable: 
Number of patients with trypanosomes detected in the blood, lymph-
node aspirate or CSF at any follow-up examination (and without 
distinction between relapse and re-infection) as a percentage of the 
number of patients who received at least one dose of treatment and 
were discharged alive from the hospital. 
(b) Should patients treated for second-stage HAT and for whom no 
trypanosomes are detectable in blood, lymph or CSF, but who are 
suspected to have relapsed based on an increase in the CSF WBC count of 
> 10 cells/µl be included in the calculation of treatment failure rate? Or 
should those patients be quantitated separately to obtain a secondary 
efficacy variable? 
(c) Should patients without parasites in blood, lymph or CSF and without a 
CSF WBC count of > 10 WBC/µl CSF (e.g. patients who refuse to 
undergo a lumbar puncture) who are suspected to have relapsed based on 
signs and symptoms of the disease be included among patients in the 
calculation of the treatment failure rate? Or should ‘clinically suspected 
relapses’ be quantified separately to obtain a secondary efficacy variable? 
(d) Should the primary efficacy variable instead be the ‘failure rate’ calculated 
as the sum of the number of patients who: 
 had parasites in the blood, lymph or CSF at the EoT; 
 relapsed (i.e. with demonstrated presence of parasites in the CSF) 
before or at the chosen efficacy end-point time); 
 suspected to have relapsed based on WBC count > 10 WBC/µl CSF 
and/or signs and symptoms of HAT; 
 died during treatment or follow-up with death due to HAT; 
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 died during treatment or follow-up due to drug-related or disease-
related adverse events; or who 
 died during follow-up with unknown cause of death, 
 as a percentage of all patients who received at least one dose of treatment?  
(e) Are the following suitable secondary efficacy variables: 
 Relapse rate or failure rate in the ‘per-protocol’ population, 
calculated as the number of patients in whom treatment failed/or who 
relapsed before or at the chosen efficacy end-point time (as defined 
for the primary efficacy parameter) or as the number of patients who 
failed treatment (see above for primary efficacy variable) as a 
percentage of the number of patients discharged alive from the 
hospital who received treatment as planned in the protocol? 
 Response rate at EoT: the percentage of patients released from the 
hospital with no evidence of parasites in the CSF, blood or lymph 
among all patients treated (intent-to-treat) and all patients treated as 
per protocol? 
 Fatality rate at the EoT: the percentage of patients who died due to 
HAT before the scheduled EoT among all patients treated? 
(f) Can ‘time to relapse’ or ‘time to failure’ statistics provide additional or 
better assessment of efficacy than calculation of rates? 
18 A database to support the conclusion that a new drug is adequately safe and 
effective has nowadays to include data from at least two independently conducted 
clinical studies, both showing similar results. The exact requirements tend to be 
indication-specific.  
(a) Given the small number of sites available at any one time to conduct 
clinical studies in HAT patients according to GCP, the large number of 
patients that need to be screened and the fact that each site has only a 
limited ‘lifetime’: 
 Is it feasible to conduct two independent trials, both powered for 
statistical significance (estimated at around 500–600 patients)? 
 Is it feasible to conduct one trial powered for statistical significance 
and a second smaller ‘supportive’ study? 
 Can one appropriately-powered trial provide sufficient evidence of 
the safety and efficacy of a new treatment modality in HAT? 
 How can the limiting factors (resources, site personnel recruitment 
and training, study conduct, active follow-up) for site build-up be 
reduced? 
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